Official Title:  A Phase 2 Study to Assess the Efficacy and Safety of  TGR -1202
(Umbralisib) Monotherapy in Patients with Non-Follicular Indolent 
Non-Hodgkin’s Lymphoma
Study ID: [REMOVED]
Document  Date : Protocol Version 2.0: 05 -September -2017
TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 1 of 68 Protocol version/Date:    Version 2.0 / 5 September , 201 7 
Local Protocol #:    Protocol TGR -1202- 202  
TITLE:  
A Phase 2 Study to Assess the Efficacy and Safety of TGR -1202 (Umbralisib)  Monotherapy in 
Patients with Non -Follicular Indolent Non -Hodgkin’s Lymphoma  
 
Sponsor:    TG Therapeutics, Inc.  
    2 Gansevoort St., 9th Floor  
    New York, NY 1001 4 
    Tel: (212) 554- 4484  
 
IND Number:    TGR -1202  
116,762  
     
 
Study Chair :    , M.D., FACP, FAAAS, FASCO  
 
 
 
 
 
 Medical M
onitor:   , MD  
    Tel: (212) 554- 4484  
  
Study Coordination:   TG Therapeutics, Inc.  
    2 Gansevoort Street, 9th Floor  
    New York, NY 10019  
    Tel: (212) 554- 4484  
 
Version:  1.0        Date:   4 April 2017  
Version : 2.0         Date : 5 September 2017  
 This document is a confidential communication of TG Therapeutics, Inc. Acceptance of this document 
constitutes agreement by the recipient that no unpublished information contained herein shall be 
published or disclosed without prior written approval, except that this documen t may be disclosed to 
the appropriate In stitutional Review Boards/ Independent Ethics Committees under the condition that 
they keep it confidential.  
 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 3 of 68 PROTOCOL ACCEPTANCE FORM  
Protocol Title:  A Phase 2 Study to Assess the Efficacy and Safety of TGR -
1202 (Umbralisib)  Monotherapy in Patients with Non -
Follicular Indolent Non -Hodgkin’s Lymphoma  
Protocol Number:  TGR -1202 -202 
IND Number:  TGR -1202   
116,762   
Date FINAL:  5 September  2017  
 
I have read the attached protocol and agree that it contains all the necessary details for performing 
TGR- 120 2-202. 
I will provide copies of the protocol and of the TGR -1202 (umbralisib)  Investigator ’s Brochure, which 
was given  to me by TG Therapeutics (Sponsor), to all members of the study team for whom I am 
responsible and who participate in the study.  I will discuss this material with them to ensure that 
they are fully informed regard ing TGR -1202 , as well as the Standard of Care agents used in this trial,  
and the conduct of the study.  
Once the protocol has been approved by the IRB, I will not modify this protocol without obtaining the prior approval of TG Therapeutics and of the IRB.  I will submit the protocol modifications and/or any informed consent modifications to TG Therapeutics and the IRB, and approval will be obtained 
before any modifications are implemented.  
I understand the protocol and will work according to it, the principl es of Good Clinical Practice 
(current ICH guidelines), and the Declaration of Helsinki (1964) including all amendments up to and 
including the Washington Clarification (2002).  
 
 
     
Print Name   Signature   Date  
 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 4 of 68 TABLE OF CONTENTS 
STUDY SYNOPSIS  ................................................................................................................................... 9  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ....................................................... 14 
1 INTRODUCTION ................................................................................................................................ 16 
1.1 Indolent non -Hodgkin’s Lymphoma  .................................................................................................................. 16 
1.2 TGR -1202 (UMBRALISIB)  ...................................................................................................................................... 17 
1.2.1 Pre -Clinical Development of TGR -1202  ................................................................................................................................................... 17 
1.2.2 Clinical Development of TGR -1202 ............................................................................................................................................................ 19 
1.3 Rationale for Recommended Phase 2 Dose of TGR -1202  ......................................................................... 21 
1.4 Rationale for Phase 2 Study  .................................................................................................................................. 22 
2 OBJECTIVES AND ENDPOINTS  ..................................................................................................... 23 
2.1 Study Objectives  ........................................................................................................................................................ 23 
2.2 Effi cacy Endpoints  .................................................................................................................................................... 23 
3 ELIGIBILITY CRITERIA  ................................................................................................................... 24 
3.1 Inclusion Criteria  .......................................................................................................................................................  24 
3.2 Exclusion Criteria  ...................................................................................................................................................... 24 
4 STUDY DESIGN  .................................................................................................................................. 26 
4.1 Overview of Study Design  .......................................................................................................................... 26 
4.2 Registration  ................................................................................................................................................................. 26 
4.3 Study Si tes ....................................................................................................................................................................  26 
4.4 Discontinuation from Study Treatment  ........................................................................................................... 26 
5 STUDY ASSESSMENTS AND TREATMENT SCHEDULE  .......................................................... 28 
5.1 Study Assessments and Treatment Schedule  ................................................................................................ 28 
5.2 Laboratory Assessments  ........................................................................................................................................ 29 
5.2.1 Local Laboratory Assessments  ..................................................................................................................................................................... 29 
5.2.2 Central Laboratory Assessments  ................................................................................................................................................................. 29 
6 TREATMENT PLAN  .......................................................................................................................... 30 
6.1 Treatment Summary  ................................................................................................................................................ 30 
6.2 Agent Administration  .............................................................................................................................................. 30 
6.2.1 Guidelines for Administration of TGR -1202(UMBRALISIB)  .......................................................................................................... 30 
6.2.2 Criteria for Ongoing Treatment .................................................................................................................................................................... 31 
6.3 Dosing Delays and Modifications  ........................................................................................................................ 31 
6.3.1 Dose Delay/Modification Recommendations: TGR- 1202 ................................................................................................................ 31 
6.4 Ordering TGR -1202  .................................................................................................................................................. 33 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 5 of 68 6.5 Duration of Therapy  ................................................................................................................................................. 33 
7 STUDY MEDICATIONS OVERVIEW AND SAFETY  ................................................................... 34 
7.1 TGR -1202(UMBRALISIB)  ....................................................................................................................................... 34 
7.1.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRs)  ....................................................................................... 34 
8 MEASUREMENT OF EFFECT  .......................................................................................................... 36 
8.1 Method of Assessment  ............................................................................................................................................ 36 
8.2 Response Review  .......................................................................................................................................................  36 
8.3 Anti tumor Effect  ........................................................................................................................................................ 36 
8.4 Definitions of Tumor Response and Progression  ........................................................................................ 37 
8.4.1 Complete Response  ............................................................................................................................................................................................ 37 
8.4.2 Very Good Partial Response  ........................................................................................................................................................................... 37 
8.4.3 Partial Response  .................................................................................................................................................................................................. 37 
8.4.4 Minor Response  ................................................................................................................................................................................................... 38 
8.4.5 Stable Disease  ....................................................................................................................................................................................................... 38 
8.4.6 Relapsed Disease or Progression of Disease  .......................................................................................................................................... 38 
8.5 Definitions of Disease Parameters  ..................................................................................................................... 38 
8.6 Evaluation of Best Overall Response  ................................................................................................................. 39 
8.6.1 Duration of Response  ........................................................................................................................................................................................ 39 
9 STATISTICAL CONSIDERATIONS  ................................................................................................. 40 
9.1 Sample Size and Power  ........................................................................................................................................... 40 
9.2 General Analysis Convention  ................................................................................................................................ 40 
9.3 Analysis Populations  ................................................................................................................................................ 40 
9.4 Patient Disposition  ................................................................................................................................................... 40 
9.5 Patient Demographics and Baseline Characteristics  .................................................................................. 41 
9.6 Medi c
al History  ..........................................................................................................................................................  41 
9.7 Extent of Exposure  .................................................................................................................................................... 41 
9.8 Efficacy Analyses  .......................................................................................................................................................  41 
9.9 Missing Value Handling Procedures  .................................................................................................................. 41 
9.10 Statistical Analyses  ................................................................................................................................................ 41 
9.10.1 Primary Efficacy Variable ............................................................................................................................................................................. 41 
9.10.2 Efficacy Variable  ............................................................................................................................................................................................... 42 
9.11 Multiple Comparison Procedures  .................................................................................................................... 42 
9.12 Safety Analyses  ........................................................................................................................................................ 42 
9.13 Adverse Event Characteristics  .......................................................................................................................... 42 
9.14 Definitions of Adverse Events  ........................................................................................................................... 42 
9.15 Adverse Events (AE’s) and Treatment Emergent Adverse Events (TEAE’s)  ................................. 43 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 6 of 68 9.16 Adverse Events/Serious Adverse Event Causality Assessment  ..........................................................  43 
9.16.1 Recording of Adverse Events  ...................................................................................................................................................................... 44 
9.16.2 Abnormal Laboratory Values and Vital Signs  ..................................................................................................................................... 44 
9.16.3 Handling of Adverse Events  ........................................................................................................................................................................ 45 
9.17 Serious Adverse Events  ........................................................................................................................................ 45 
9.17.1 Definitions of Serious Adverse Events  ................................................................................................................................................... 45 
9.17.2 Serious Adverse Event Reporting by Investigators  ......................................................................................................................... 46 
9.18 Sponsor SAE Reporting Requirements  ..........................................................................................................  47 
9.19 Recording of Adverse Events and Serious Adverse Events  ................................................................... 47 
9.20 Diagnosis vs. Signs and Symptom s .................................................................................................................. 47 
9.20.1 Persistent or Recurrent Adverse Events  ............................................................................................................................................... 47 
9.20.2 Abnormal Laboratory Values  ..................................................................................................................................................................... 48 
9.20.3 Deaths  .................................................................................................................................................................................................................... 48 
9.20.4 Hospitalization, Prolonged Hospitalization, or Surgery  ................................................................................................................ 48 
9.20.5 Pre -Existing Medical Conditions  ............................................................................................................................................................... 48 
9.20.6 Protocol -Defined Events of Special Intere st ........................................................................................................................................ 49 
10 CLINICAL DATA COLLECTION AND MONITORING  .............................................................. 50 
10.1 Site Monitoring  ........................................................................................................................................................ 50 
10.2 Amendments to the Protocol  ............................................................................................................................. 50 
10.3 Curricula Vitae and Financial Disclosures  ....................................................................................................  51 
10.4 Data Ownership and Publication  .....................................................................................................................  51 
11 ETHICAL, FINANCIAL, AND REGULATORY CONSIDERATIONS  ....................................... 52 
11.1 IRB Approval  ............................................................................................................................................................ 52 
11.2 Regulatory Approval  ............................................................................................................................................. 52 
11.3 Informed Consent  ...................................................................................................................................................  52 
11.4  C
onfidentiality ..........................................................................................................................................................  53 
11.5 Investigator and Staff Information  .................................................................................................................. 54 
11.6 Financial Information  ........................................................................................................................................... 54 
12 RECORD RETENTION AND DOCUMENTATION OF THE STUDY  ...................................... 55 
12.1 Documentation Required to Initiate Study  .................................................................................................. 55 
12.2 Study Documentation and Storage  .................................................................................................................. 55 
12.3 Data Collection  ......................................................................................................................................................... 57 
12.4 Study Monitoring, Auditing, and Inspecting  ................................................................................................ 57 
12.5 Quality Assurance and Quality Control  ......................................................................................................... 57 
12.6 Disclosure and Publication Policy .................................................................................................................... 58 
13 REFERENCES  ................................................................................................................................... 59 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 7 of 68 14 Appendix A –Criteria for Response Assessment  ................................................................ 61 
15 Appendix B - Contraceptive Guidelines and Pregnancy  ................................................... 65 
16 Appendix C – NYHA Classifications ......................................................................................... 67 
17 Appendix D – Hepatitis B Serologic Test Results  ............................................................... 68 
 
  
 
     
 
     
 
    
 
   

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 8 of 68 Version 2. 0 (Dated 5 September 2017) of this Protocol is the second amendment to this clinical trial 
and contains the following modifications:  
• Section 2.1 has been updated to include  
• Section 3.2 has been updated to broaden the Exclusion Criteria to include any significant 
cardiovascular disease within  6 months  
• Sections 4.1, 6.5, and 8 have been updated to reflect the change in scan assessment schedule and to include response assessment for WM patients without nodal involvement. In addition, 
these sections have been updated to include the follow -up sche dule for patients who 
discontinued from the study for reason other than disease progression.  
• Updates on the Study Assessment and Treatment Schedule in Section 5  
• Section 5.2.2 has been included to add Central Laboratory Assessments  
• Section 6.2.1 has been updated to require treatment with pneumocystis jiroveci pneumonia 
(PCP) and antiviral therapy  
• Section 6.3.1 has been updated to provide detailed guidance for TGR -1202 Dose Delays and 
Modifications 
• Section 7.1.1 has been updated to include the latest CAEPRS  information for TGR -1202.  
• Appendix B has been updated for  male  patients to use highly effective contraception during 
the study period and for 30 days  after.  
• Updated throughout to acknowledge the tradename for TGR -1202: umbralisib  
• Minor administrative updates and typographical errors were corrected throughout.   
 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 16 of 68 1 INTRODUCTION  
1.1 INDOLENT NON -HODGKIN ’S LYMPHOMA  
Non -Hodgkin ’s lymphomas are a heterogeneous group of disorders with different pathophysiology, 
histology and clinical course. The i ndolent non-Hodgkin ’s lymphomas (iNHL) are a subset of B -cell 
Non -Hodgkin ’s Lymphomas characterized by prolonged median survival with a long relapsing and 
remitting clinical course. These i ndolent lymphomas are slow growing, spread slowly with few 
presenting symptoms. Follicular l ymphoma grades I -IIIa tend to be slow growing and are the most 
prevalent lymphoma in this disease group.  The remainder of indolent lymphomas are non- follicular 
indolent lymphomas comprising of small l ymphocytic lymphoma , marginal zone B - cell lymphoma 
(nodal , splenic and extra nodal ) and l ymphoplasmacytic lymphoma/ Waldenstrom’s 
macroglobulinemia1 . 
In the US, there are an estimated 16000 new cases of n on-follicular i ndolent lymphomas diagnosed 
every year. Indolent non-Hodgkin ’s lymphoma is a disease of the older population with the median 
age of diagnosis varying from 65 to 72 years. The average median survival for non–follicular i ndolent 
non-Hodgkin ’s lymphomas is 10 – 15 years (SEER Stat Fact Sheets: Non -Hodgkin ’s Lymphoma. 
Bethesda, MD: National Cancer Institute; 2013) For a disease with such a protracted course the goal 
of management has been to maintain a good quality of life and initiate treatment only when the 
patients become symptomatic. A wait and watch approach is used till the d isease becomes 
symptomatic. 2The foundation o f treatment for i ndolent non-Hodgkin ’s lymphomas is 
chemoimmunotherapy (mainly CD -20 antibody like rituximab ) used alone or in combination with 
chemotherapy consisting of anthracycline, alkylating and purine analogues for use as a first line agent 
and in relapsed or refractory disease.  3,4 The response rate and progression free survival of Rituximab 
monotherapy or combination therapy is reassuring however as many as 20 -30% patients relapse 
within 3 years of treatment with  first -line chemoimmunotherapy.5–7 Relapsed or refractory iNHL 
have poor overall survival. Furthermore, the responses to second line therapies are inferior 
suggesting a need for better salvage therapy after first line therapies 
Recently the FDA provided accelerated approval for the PI3K inhibitor, idelalisib to treat patients 
with relapsed follicular B -cell non -Hodgkin ’s lymphoma (FL) and relapsed small lymphocytic 
lymphoma (SLL) who have received at least two prior systemic therapies . This was based on a 
randomized clinical trial involving 123 patients which showed an overall response rate of 57% and 
a median progression free survival of 11 months. However up to 54 % of patients in th e clinical trial 
experienced a grade 3 or higher adverse event, with discontinuation of idelalisib in 20 % of the 
patients. Some of the most frequently reported adverse events of grade 3 or higher were diarrhea (in 
13% of the patients), pneumonia (in 7%), and dyspnea (in 3%).  Discontinuation or interruptions led 
to response durations that were shorter lived.8 Another clinical trial involving idelalisib for treatment 
of CLL showed a similar adverse effect profile.  Given the increasing rate of adverse effects including 
death, FDA has placed six clinical trials on hold for patients receiving idelalisib for chronic 
lymphocytic leukemia, small lymphocytic lymphoma and indolent non -Hodgkin ’s lymphoma.  
Given an improved tolerability profile observed to date, we have selected TGR -1202(umbralisib)  to 
study in patients with relapsed/refractory n on-follicular i ndolent non-Hodgkin ’s lymphomas . 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 18 of 68 FIGURE 2: REDUCTIO N OF PAKT BY TGR -120 2 IN CELL LINES BY W ESTERN BLOTTING  
 
1.2.1.1 IN-VIVO ACTIVITY  
In vivo efficacy of TGR -1202 was confirmed in a subcutaneous mouse MOLT- 4 xenograft model.  Oral 
administration of 150 mg/kg/QD over a 25 -day period resulted in a significant delay in tumor 
growth.  
FIGURE 3: TGR -1202 IN VIVO E FFICACY  
 
1.2.1.2 TOXICOLOGY   
To assess the safety and toxicity of TGR -1202 a 28- day repeat dose study with a 14 -day recovery 
period was conducted in CD -1 mice and beagle dogs, to evaluate the potential reversibility of findings 
and to support the use in humans.  TGR -1202 was administe red orally in order to mimic the planned 
mode of clinical administration.       
Once daily oral administration of TGR -1202 was tolerated in mice at free base dose levels of 50 and 
150 mg/kg/day.  Increases in liver weights, microscopic findings in the liver and the increases in 
serum cholesterol, and female only ALT, AST, and GGT levels were observed at 750 mg/kg/day of free base (the highest dose tested) and were considered adverse.  The no -observed -adverse -effect 
level (NOAEL) was considered to be 150 mg/kg/day in mice.  
Once daily oral administration by capsule of TGR -1202 was well tolerated in dogs at levels of 50 and 
150 mg/kg/day.  The gastrointestinal tract, based on clinical signs, was the target organ system.  Based on effects on body weight and the  incidence and severity of emesis and diarrhea, the NOAEL 
was considered to be 150 mg/kg/day (114.5 mg/kg/day as free base) in this species.  
Refer to the TGR- 1202 Investigator’s Brochure (IB) for detailed information on toxicology studies 
conducted to date . 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 19 of 68 1.2.2 CLINICAL DEVELOPMENT  OF TGR -1202   
1.2.2.1 SINGLE -AGENT IN PATI ENTS WITH RELAPSED OR REFRACTORY HEMATOL OGIC 
MALIGNANCIES  
TGR- 1202 was evaluated in a Phase I dose -escalation study in patients with relapsed and refractory 
hematologic malignancies  (O’Connor et al, ASH 201 5).  As of the latest cutoff date for this study of 
December  201 5, 81 patients were enrolled and eligible for safety evaluation, with 63  patients 
evaluable for efficacy.  The median age was 6 5 years (range 22 -85), 53/28 male and 14/ 81 enrolled 
patien ts had a diagnosis of DLBCL.  Among all patients,  the median number of prior therapies was 3  
(range, 1- 14), with 57% of patients having 3 or more prior therapies and 49 % refractory to their 
immediate prior therapy .   
Patients have been enrolled in a 3+3 do se-escalation design starting at 50 mg QD with subsequent 
cohorts evaluating doses as high as 1800 mg QD.  In an effort to further improve the oral 
bioavailability of TGR -1202, the particle size of the drug product was reduced through a 
micronization proce ss, resulting in greater absorption when tested in a bioequivalence crossover 
study in healthy subjects (see Section 1.2.2.2 Healthy Subject Pharmacokinetic Studies  below).  
Additionally, a healthy subject food effect study as well as data from the patients in the fed -state 
expansion cohorts revealed increased exposure in the fed state.  As a result of these improvements, 
dose- escalation has proceeded using the micronized formulation in a fed state.  This micronized 
formulation was introduced into dose escalation at 200 mg QD and dosed as high as 1200 mg QD, 
with no maximum tolerated dose (MTD) reached.  Intra- patient dose escalation rules have allowed 
patients enrolled into the study in early cohorts to increase their dose of TGR -1202 as subsequent 
higher cohorts have cleared safety evaluation.  A dose -dependent response has been observed with 
TGR- 1202 (ASCO 2013), with a dose of 800 mg or higher of the initial formulation or any dose of the 
micronized formulation producing significant nodal reductions among CLL patients.  Of t he 17 CLL 
patients treated at ≥800mg , 94% have achieved a nodal partial response, and nodal reductions show 
an improvement with time on TGR -1202 with a median time on stu dy of 6 months.  Adverse events 
observed amongst all 55 patients included diarrhea, nausea, fatigue, cough, anorexia, headache, 
vomiting, rash, neutropenia, constipation, dyspnea, and thrombocytopenia.  One DLT event of Grade 3 rash was observed at the 800  mg dose level of the initial formulation, which necessitated 
enrollment of an additio nal 3 patients.  The Grade 3 rash resolved upon suspension of TGR -1202 and 
concomitant medications and did not recur upon re- challenging the patient at 800  mg QD.  See 
Section 7.1.1  for a complete overview of the TGR- 1202 side 
effect profile.   
1.2.2.2 HEALTHY SUBJECT PHARMACOKINETIC STUD IES 
In parallel with the Phase I single -arm, dose -escalation study in patients with relapsed or refractory 
hematologic malignancies; two healthy subject, crossover, bioequivalence pharmacokinetics studies 
have been completed.  The first  pharmacokinetic study was a Phase I drug- food interaction study 
with a single 200 mg oral dose of TGR -1202 in healthy volunteers followed by a second single dose 
Phase I pharmacokinetic study evaluating the absorption, distribution, metabolism and excreti on 
characteristics of two different oral formulations of 200 mg TGR -1202 (original formulation vs. 
micronized formulation) in healthy volunteers.  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 21 of 68 relative to original drug product formulation.  The Peak plasma ( Cmax) levels of TGR -1202 increased 
by over 124% following administration of the micronized drug product formulation relative to 
original drug product formulation under fasted conditions.  
Using these mean values, a 320 mg oral dose of TGR -1202 in the original formulation under fasted 
condition can be extrapolated to be equivalent to an oral dose of 200 mg of the original formulation TGR- 1202 under fasted conditions in term of exposure based on AUC
0-inf.  
The improved exposure seen with the micronized formulation of TGR -1202 was confirmed in 
patients in the Phase 1 dose escalation as well.  The chart below illustrates the pre- dose plasma 
concentrations of TGR -1202 on Day 1 of Cycle 2 in patients administered equivalent doses of either 
the ini tial formulation in the fasting state or the micronized formulation in the fed state:   
 
1.3 RATIONALE FOR RECOMM ENDED PHASE 2  DOSE OF TGR -1202 
In this Phase 2  study, 800 mg dose of TGR -1202 will be orally administered under fed conditions 
using the micronize d drug product formulation.  The two Phase I pharmacokinetic studies have 
elucidated that:  
• The systemic exposure to TGR -1202 increases approximately 67% based on total extent 
(AUC 0-inf) under fed condition; and  
• The systemic exposure to TGR -1202 increases approximately 60% based on the modified 
drug product formulation when compared to the original drug product formulation.  
To evaluate the improvement in the absorption of TGR -1202 with the modified drug product 
formulation under fed condition, the Phase I d ose-escalation study with TGR -1202 includes the 
following dose groups:  
• Administration of original drug product formulation under fasted and fed conditions; and  
• Administration of the modified drug product formulation under fed conditions.  
Based on the resu lts from the completed Phase 1 dose- escalation study and the two Phase I 
pharmacokinetics studies in healthy volunteers, a dose of 800 mg of TGR -1202 using the modified 
drug product formulation under fed condition was selected.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 22 of 68 1.4 RATIONALE FOR PHASE 2 STUDY   
Based on the success of P hase I trials of PI3K inhibitor i delalisib in patients with iNHL Gopal et al 
performed a Phase 2 randomized clinical trial involving 123 patients with relapsed and refractory 
iNHL with prior rituximab and alkylator based therapy.   After a median follow -up of 9.7 months , the 
median time to a response was 1.9 months, the median duration of response was 12.5 months, and 
the median progression -free survival was 11 months. The response rate was 57% (71 of 125 
patients), with 6% meeting  the criteria for a complete response. However up to 54 % of patients in 
the clinical trial experienced a grade 3 or higher adverse event, with discontinuation of i delalisib in 
20 % of the patients. Some of the most frequently reported adverse events of grade 3 or higher were 
diarrhea (in 13% of the patients), pneumonia (in 7%), and dyspnea (in 3%)8. Combining i delalisib 
with other agents resulted in greater episodes of grade 3 or  higher events including death. In addition 
to autoimmune toxicity multiple episodes of severe sepsis were reported with increasing 
opportunistic infections suggesting possible immune deficiency.11–13  A recent safety analysis of 3 
Phase III studies in subjects with previously untreated CLL (bendamustine /rituximab ± idelalisib) 
and previously treated indolent B- cell NHL (rituximab ± idelalisib and bendamustine/rituximab ± 
idelalisib ) were recently halted because of an excess of deaths and serious adverse events among 
patients treated in the idelalisib -containing groups (combined mortality rate, 49/664 [7.4%] vs 
14/402 [3.5%])  
TGR- 1202  (umbralisib)  is a PI3K inhibitor with an improved safety profile. In an integrated analysis 
of two Phase I studies, 165 patients with non- Hodgkin ’s lymphoma, including CLL, were treated with 
TGR- 1202.  Adverse events such as nausea, diarrhea, fatigue, headache, vomiting and  cough were the 
most commonly reported events, the majority of which were Grade 1 and 2.  The only Grade ≥3 
adverse event in more than 10% of patients was neutropenia (18%).  Discontinuation due to an 
adverse event with TGR -1202 was reported 8% of patients . 
 
The purpose of this study is to evaluate the safety and efficacy of TGR -1202 in previously treated 
non-follicular i ndolent non-Hodgkin ’s lymphoma patients.   

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 23 of 68 2 OBJECTIVES AND ENDPOINTS  
2.1 STUDY OBJECTIVES  
PRIMARY OBJECTIVES  
• To evaluate the overall response rate (CR + PR + VGPR  + MR ) and duration of response for 
TGR- 1202 in patients with relapsed or refractory non -follicular indolent non -Hodgkin ’s 
lymphoma .   
SECONDARY OBJECTIVES  
• To determine the progression free survival of TGR- 1202 in patients with relapsed  or refractory 
non- follicular indolent non -Hodgkin ’s lymphoma.  
• To evaluate time to treatment failure with TGR -1202. 
• To evaluate the safety profile of TGR -1202  
 
 
2.2 EFFICACY ENDPOINTS  
Progression -free survival (PFS) 
 
PFS is defined as the interval from Cycle 1/Day 1 to the earlier of the first documentation of definitive 
disease progression or death from any cause. Definitive disease progression based on revised 
response criteria for malignant lymphoma (Cheson et al, 2014 and Owen et al 2013 ).  
 
Time to treatment failure (TTF)   
TTF is defined as a composite endpoint measuring time from Cycle 1/Day 1 to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death.  
Overall res ponse rate (ORR)  
 
ORR is defined as sum of CR and PR  (and VGPR , MR  for patients with WM)  rates.  
 
Duration of response (DOR)  
 DOR is defined as the interval from the first documentation of CR or PR or VGPR  or MR to the earlier 
of the first documentation of definitive disease progression or death from any cause.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 24 of 68 3 ELIGIBILITY CRITERIA  
Patients must meet all of the following inclusion criteria and none of the exclusion criteria to be 
eligible for participation in this study.  
 
3.1 INCLUSION CRITERIA  
Patients must meet all of the following inclusion criteria to be eligible for participation in this study:  
1. Histologically confirmed diagnosis of B -cell non-follicular i ndolent non-Hodgkin ’s lymphoma 
meeting following requirements.   
a. World Health Organization 2008 classification criteria  warranting therapy as per 
investigator discretion for histologies limited to s plenic marginal z one lymphoma 
(SMZL), nodal m arginal zone Lymphoma (NMZL), or extra -nodal marginal z one 
lymphoma (ENMZL), and lymphoplasmacytic lymphoma . 
b. Presence of CD20+ lymphoplasmacyt ic lymphoma involving the bone marrow, positive 
serum immunofixation for monoclonal IgM and atleast one criteria for initiation of 
treatment as per Consensus panel of International Workshops on Waldenstrom ’s 
macroglobulinem ia. 
2. Relapsed or refractory after at least one prior treatment regimen, with no limit on prior 
therapies.  
3. At least 1 measurable disease lesion >1.5 cm in at least one diameter by CT/CT -PET or 
magnetic resonance imaging (MRI) in an area of no prior radiation  therapy, or in an area that 
was previously irradiated that has documented progression.  
a. Exceptions include for Waldenstrom ’s macroglobulinemia patients without nodal 
involvement.  
4. Waldenstrom’ s macroglobulinemia patients must have measurable quantitative Ig M 
monoclonal protein greater than normal value.  
5. Adequate organ system function, defined as follows:  
a. Absolute neutrophil count (ANC) > 1,000 / platelet count > 50,000.  
b. Total bilirubin ≤1.5 times the upper limit of normal (ULN)  
c. Alanine aminotransferase (ALT)  and aspartate aminotransferase (AST) ≤2.5 x ULN if 
no liver involvement or ≤5 x the ULN if known liver involvement  
d. Calculated creatinine clearance >30 mL/min (as calculated by the Cockcroft -Gault or 
MDRD formula, 24 - hour urine Cr clearance also acceptable)  
6. ECOG performance status ≤ 2 
7. Male or female ≥ 18 years of age 
8. Ability to swallow and retain oral medication  
9. Female patients who are not of child -bearing potential and female patients of child -bearing 
potential who have a negative serum pregnancy test within 3 days prior to Cycle 1, Day 1.  
10. Willingness and ability to comply with trial and follow -up procedures, and give written 
informed consent  
3.2 EXCLUSION CRITERIA  
Patients who meet any of the following exclusion criteria are not to be enrolled to this study:  
1. Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, 
biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational 
drug within 21 days of Cycle 1/Day 1.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 25 of 68 a. Corticosteroid therapy started at least 7 days prior to study entry (prednisone ≤10 mg daily 
or equivalent) is allowed as clinically warranted.  Topical or inhaled corticosteroids are 
permitted  
2. Refractory to idelalisib, duvelisib, or any drug that specifically inhibits phosphoinositide -3-
kinase (PI3K).   
3. Prior autologous stem cell transplant within 6 months.  Prior allogeneic hematologic stem cell 
transplant is excluded.   
4. Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody) or chronic active Hepatitis C infection (HCV), 
cytomegalovirus (CMV), or known history of HIV. If HBc antibody, HCV antibody or CMV is 
positive the subject must be evaluated for the presence of HBV, HCV, or CMV by DNA (PCR) - See 
Appendix D.  
5. Known histological transformation to an aggressive lymphoma  
6. Known Central Nervous System (CNS) lymphoma; patients with symptoms of CNS disease must have a negative CT scan and negative diagnostic lumbar puncture.  
7. Evidence of ongoing systemic ba cterial, fungal or viral infection, except localized fungal infection 
of skin or nails.  NOTE:  Patients may be receiving prophylactic antiviral or antibacterial therapies at investigator discretion.  
8. Any severe and/or uncontrolled medical conditions or oth er conditions that could affect their 
participation in the study such as:  
a. Symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III- IV) – See Appendix C  
b. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of randomization  
c. QTc Interval >470  
d. Angina not well -controlled by medication  
e. Poorly controlled or clinically significant atherosclerotic vascular disea se including 
cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, 
cardiac/vascular stenting within 6 months of enrollment  
9. Malignancy within 3 years of study enrollment except for adequately treated basal, squamous cell carcinoma or  non- melanomatous skin cancer, carcinoma in situ of the cervix, superficial 
bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized 
prostate cancer and PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart  
with the most recent one being within 4 weeks of study entry.  
10. Women who are pregnant or lactating. 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 26 of 68 4 STUDY DESIGN  
4.1 OVERVIEW OF STUDY DE SIGN  
This study is designed as a Phase 2  trial to evaluate the efficacy and safety of TGR -1202  (umbralisib)  
monotherapy  in previously treated n on-follicular i ndolent non-Hodgkin’s lymphoma . Patients are 
required to have n on-follicular i ndolent non-Hodgkin’s lymphoma  that is relapsed or refractory 
following at least one prior standard therapy regimen .   
 
Enrollment  
Following Screening, qualified patients will be administered TGR -1202 monotherapy at 800 mg QD.  
 
During the study period, all patients will be evaluated for response by CT, PET -CT and/or MRI every 
3 cycles . For patients with WM without nodal involvement, response wi ll be assessed by quantitative 
monoclonal IgM protein every 3 cycles.  The best clinical response as well as disease progression will 
be determined by local investigator.  Patients will remain on study treatment until the occurrence of 
definitive disease pro gression, unacceptable toxicity, or withdrawal from the study due to 
investigator decision or other reasons.  Patients who discontinue from study treatment (either for 
toxicity or physician choice) and have not progressed should  continue to be followed for  progression  
every 6 months or per standard of care . 
An independent DSMB will be established to advise the Sponsor on safety and ethical issues of the study.  Once the database has been locked, the independent DSMB will review the primary and secondary efficacy analyses and safety data.  
4.2 REGISTRATION  
Patients who are eligible and who have signed an informed consent will be enrolled in the trial with 
TGR- 1202 monotherapy.  
4.3 STUDY SITES  
 
Up to 5 centers in the United States may be asked to participate in this study .   
4.4 DISCONTINUATION FROM  STUDY TREATMENT 
Patients may be discontinued from study treatment for any of the following reasons:  
• Disease progression  
• Intolerable toxicity related to study drug  
• Patient requests to withdraw consent or discontinue treatment  
• Pregnancy 
• Inability of the patient to comply with study requirements  
• Conditions requiring therapeutic intervention not permitted by the protocol  
• Non -compliance/lost to follow -up 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 27 of 68 • Investigator discretion  
• Discontinuation of the study by the Sponsor  
Patients w ho discontinue from study treatment (for reasons other than progressive disease) will 
continue to be followed for progression.  
After discontinuation from protocol treatment, patients should be followed for AEs for 30 calendar 
days after their last dose of either study drug.  All new AEs occurring during this period must be 
reported and followed until resolution, unless, in the opinion of the investigator, these values are not 
likely to improve because of the underlying disease.  In this case the investigato rs must record his or 
her reasoning for this decision in the patient’s medical records and as a comment on the electronic Case Report Form (eCRF).  
All patients who have CTCAE grade 3 or 4 laboratory abnormalities at the time of withdrawal should be followe d until the laboratory values have returned to grade 1 or 2, unless in the opinion of the 
investigator, it is not likely that these values are to improve because of the underlying disease.  In this case, the investigator must record his or her reasoning fo r making this decision in the patient’s 
medical records and as a comment on the eCRF.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 31 of 68 Before dispensing, the site pharmacist or his/her representative must check that the TGR -1202 is in 
accordance with the product specifications and the validity is within the re -test date.  
The exact dose and the date of administration of TGR -1202 must be recorded within the eCRF, 
patient’s medical records, and/or in the drug accountability records.  For t he purpose of drug 
accountability and dosing subjects should record any missed  dose s of TGR -1202 on a drug diary.  Any 
error in drug administration should be recorded (e.g., missed dose)  in the eCRF.  
The Pharmacist or his/her representative should record t he date dispensed and patient’s number 
and initials, as well as complete the accountability record in the electronic drug accountability system  
with information concerning the dispensation of TGR -1202.  
6.2.2 CRITERIA FOR ONGOING TREATMENT 
Continue treatment as per protocol provided that patient has:  
• No intolerable toxicities related to study drug.  
o Treatment may be delayed to recover from toxicity for a maximum of one cycle.  
• No clinical or radiographic evidence of disease progression.  
• Not withdrawn from the study for other reasons.  
6.3 DOSING DELAYS AND MODIFICATIONS  
Patients should be assessed clinically for toxicity at each visit using the NCI CTCAE v4.0 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_8.5x11.pdf) grading 
scale.   Dose delay and/or modification guidance is for adverse events considered at least possibly 
related to the study drug.  If cytopenias are deemed related to the underlying disease rather than 
study drug, dose modifications are not required, or are per inve stigator discretion.  
A maximum one cycle  delay of treatment  (28 days ) for recovery from toxicity is allowed to recover  
from  hematologic toxicities to ≤  Grade 3 or non -hematologic toxicities to ≤  Grade 2 or to baseline 
level.  If greater than a one cycle  delay is necessary, then the patient should discontinue treatment 
and continue to be followed for progression.  If a patient withdraws consent or has documented 
progression, an end of study visit should be completed.  
6.3.1 DOSE DELAY/MODIFICATION RECOMMENDATION S: TGR -1202  
Supportive care should be considered for any patient who experiences Grade ≥ 2 cytopenias, or Grade ≥ 1 non -hematologic toxicities.  A maximum  28 day (1 cycle) delay for recovery from toxicity is 
allowed to allow recovery of hematologic toxicit ies to ≤Grade 3 or non -hematologic toxicities to ≤ 
Grade 2 or to baseline level.  If greater than a 28 - day delay is necessary, then the patient should 
discontinue treatment and continue to be followed for progression.  If the patient withdraws consent 
or has documented progression, an end of study visit should be completed.  
 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 34 of 68 7 STUDY MEDICATION S OVERVIEW  AND SAFETY  
7.1 TGR -1202(UMBRALISIB)  
Chemical  Name:  Umbralisib  
Other Name:   TGR- 1202  
Classification:     Phosphatidylinositol -3-Kinase (PI3K) Delta Inhibitor  
Formulation:   See Investigator Brochure   
Mode of Action :  Irreversibly inhibits activity of the Class I Delta isoform of PI3K   
How Supplied:   TGR- 1202: 200 mg tablets  
Storage:  Store at 25°C.  Excursions permitted 15°C to 30°C.  
Stability:  Retest dates will be provided periodically by Sponsor.  
Route of  
Administration : Oral  
Packaging:  TGR- 1202 is provided in HDPE bottles each containing 30 tablets and a silica 
gel canister as a desiccant.  
Availability:   TGR- 1202 is available from TG Therapeutics.  
7.1.1 COMPREHENSIVE ADVERS E EVENTS AND POTENTI AL RISKS LISTS (CAEP RS) 
The following adverse events were observed in patients treated with single agent TGR -1202  and 
were considered at least possibly related to study medication.  See the TGR -1202 investigator 
brochure for a complete list of all adverse events reported regardless of causality.  
7.1.1.1 COMMON (> 20%)  
• Gastrointestinal Disorders:  Diarrhea, Nausea  
• General Disorders and Administration Site Conditions:  Fatigue 
 
7.1.1.2 LESS COMMON (≥10% - ≤ 20%)  
• Blood and L ymphatic System Disorders:  Neutropenia  
• Gastrointestinal Disorders: Vomiting  
• Metabolism and Nutrition Diso rders: Decreased Appetite  
• Skin and Subcutaneous Tissue Disorders: Rash  
 
7.1.1.3 UNCOMMON (≥1 - <10%)  
• Blood and L ymphatic System Disorders: Anemia, Febrile neutropenia , Leukocytosis, 
Thrombocytopenia  
• Eye Disorders : Vision Blurred  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 35 of 68 • Gastrointestinal Disorders: Abdominal distension, Abdominal pain, Constipation, Dry 
mouth, Dyspepsia, Colitis  
• General Disorders and Administration Site Conditions:  Asthenia, Chills, Oedema 
peripheral, Pyrexia  
• Infections and infestations  Oral candidiasis, Pneumonia, Upper respiratory  tract infection  
• Investigations:  Alanine aminotransferase increased, Aspartate aminotransferase increased, 
Blood creatinine increased , Lymphocyte count increased, Weight decreased  
• Metabolism and N utrition Disorders:  Dehydration, Hyperglycemia, Hypokalemia,  
Hypophosphatemia,  
• Musculoskeletal and Connection  Tissue Disorders:  Arthralgia, Muscle spasms, Pain in 
extremity  
• Nervous System Disorders:  Dizziness, Dysgeusia, Headache, Neuropathy peripheral, 
Tremor  
• Psychiatric Disorders:  Insomnia  
• Respiratory, Thoracic and M ediastinal Disorders:  Cough  
• Skin and S ubcutaneous Tissue Disorders : Alopecia, Night sweats, Pruritus   
 
 
7.1.1.4 EVENTS REPORTED IN L ESS THAN 1% OF SUBJE CTS  
• Blood and Lymphatic System Disorders : Leukopenia, Hyperbilirubinemia, Bacteremia  
• Ear and Laby rinth Disorders : Tinnitus  
• Eye Disorders : Visual Impairment, Visual acuity reduced   
• Gastrointestinal Disorders : Eructation, Flatulence, Gastrooesophageal Reflux Disease, 
Abdominal Pain Upper, Mouth Ulceration, Anal Hemorrhage, Hypoaesthesia Oral, 
Paraesthesia Oral, Pancreatitis   
• General Disorders and Administration Site Conditions :  Malaise, Mucosal Inflammation,  
• Hepatobiliary Disorders : Hypocalcemia  
• Infections and Infestations :  Candida infection, Fungal skin infection, Lung infection,  
Sinusitis  
• Investigations : Internatio nal Normaliz ed Ratio Increase, Blood lactate dehydrogenase 
increase, Blood phosphorus increased, Blood sodium increased, Blood uric acid increased, 
White blood cell count decreased  
• Injury, Poisoning and Procedural Complications : Contusion  
• Metabolism and Nutrition Disorders : Hyperlipidemia , Hypertriglyceridemia, 
Hyponatremia  
• Musculoskeletal and Connective Tissue Disorders : Muscular Weakness, Myalgia, Pain in  
Jaw  
• Nervous System Disorders : Somnolence, Peripheral Sensory Neuropathy, M emory 
Impairment  
• Psychiatric Disorders : Anxiety , Libido Decrease, Delirium,  Parasomnia  
• Reproductive System and Breast Disorders : Erectile Dysfunction  
• Respiratory, Thoracic and Mediastinal Disorders : Dyspnea , Epistaxis, Hypoxia, Influenza, 
Respiratory Failure  
• Skin and Subcutaneous Tissue Disorders : Dermatitis , Dermatitis Acneiform,  
• Vascular Disorders : Hot  Flush  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 36 of 68 8 MEASUREMENT OF EFFEC T 
During the study period, all patients will be evaluated for response by CT, PET -CT and/or MRI every 
3 cycles.  All baseline assessments to characterize disease will be performed within 30 days of Cycle 
1 Day 1, prior to initiation of therapy.  During the treatment period, all efficacy assessments have a 
+/- 7 da y window.  The determination of response and progression w ill be based on the  Response 
Criteria for  non-Hodgkin ’s lymphoma , Lugano Classification (Cheson et al., 2014)  and IWWM -6 
(Owen et al 2013 ) consensus for respective disease histology . The best clinical response as well as 
disease progression will be  determi ned by the independent central radiology group (ICRG).  The 
findings of the ICRG will be considered primary for analyses of ORR, PFS, and other tumor control endpoints.  Patients who discontinue from study treatment (either for toxicity or physician choice ) 
and have not progressed will continue to be followed for progression approximately every 6 months 
or per standard of care . 
8.1 METHOD OF ASSESSMENT  
CT scan is the preferred method for radiographic tumor assessment. CT with iodinated IV contrast is 
preferred.   If iodinated contrast is contraindicated, a non -contrast chest CT coupled with a 
gadolinium- enhanced MRI of the abdomen/pelvis is an acceptable substitute.  Contrast- enhanced 
scanning is preferred, but iodine -containing or gadolinium contrast material ma y be omitted in 
patients for whom use of a contrast agent would be medically contraindicated. Chest x -ray, 
ultrasound, endoscopy, laparoscopy, or tumor markers will not be considered for response assessment.  PET -CT may also be used if per standard of care by investigator.  
 Bone marrow assessment should be used to assess response to therapy if the patient was deemed to 
have disease in the bone marrow prior to initiation of protocol therapy, per standard of care and at 
the discretion of the investigator.  
 
For radiographic evaluations, the same method of assessment and the same technique (e.g., scan type, 
patient position, dose of contrast, injection/scan interval) should be used to characterize each identified and reported lesion at baseline and during study treatment and follow -up. However, if a 
patient is imaged without contrast at baseline, subsequent assessments should be performed with contrast, unless medically contraindicated.  
8.2 RESPONSE REVIEW  
All responses will be made by local investigator assessment.  
8.3 ANTITUMOR EFFECT  
Assessme nt of lymphoma response (CR, PR, VGPR or MR) and disease progression will be evaluated 
as outlined in the schedule of events, according to the Response Criteria for non-Hodgkin ’s 
lymphoma , Lugano Classification (Cheson et al., 2014)  and IWWM -6 consensus (Owen  et al 2013 ) for 
respective disease histology . Overall response rate, CR, PR, VGPR, MR, SD, PFS and DOR will be 
calculated as detailed below.   

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 37 of 68 8.4 DEFINITIONS OF TUMOR  RESPONSE AND PROGRE SSION  
Evaluable for objective response.   Only those patients who have had a pre- treatment baseline 
efficacy evaluation and at least one post -treatment efficacy evaluation will be considered evaluable 
for response.  These patients will have their response classified according to the definitions st ated 
below.  
8.4.1 COMPLETE RESPONSE  
Complete response (CR) is defined as the complete disappearance of all evidence of disease and 
disease -related symptoms.  The spleen and/or liver, if considered enlarged before therapy, on the 
basis of physical exam or CT scan, should not be palpable on physical examination and should be 
considered normal size by imaging studies, and nodules related to lymphoma should disappear.    Bone marrow infiltrate cleared on repeat biopsy, if indeterminate by morphology, 
immunohistochemistry should be negative (Cheson et al., 20 14 Lugano Classification ).   
Previously involved nodes that were 1.1 to 1.5 cm in the long axis and more than 1.0 cm on their short 
axis before treatment must have decreased to ≤ 1.0 cm in their short axis afte r treatment (Cheson et 
al., 2014 Lugano Classification ). 
For Waldenstrom ’s macroglobulinemia patients , complete response is defined as disappearance of 
serum monoclonal IgM protein by immunofixation with a normal serum IgM level. The spleen and/or liver, i f considered enlarged before therapy, on the basis of physical exam or CT scan, should not be 
palpable on physical examination and should be considered normal size by imaging studies, and nodules related to WM should disappear. Bone marrow infiltrate clear ed on repeat biopsy, if 
indeterminate by morphology, immunohistochemistry should be negative. ( Owen et al 2013 ) 
8.4.2 VERY GOOD PARTIAL RE SPONSE  
A response criteria exclusive for Waldenstrom ’s macroglobulinemia patients, Very Good Partial 
Response (VGPR) is defined as reduction of Monoclonal IgM protein greater than 90 % from baseline. The spleen and/or liver, if considered enlarged before therapy, on the basis of physical exam or CT scan, should not be palpable on physical examination and should be considered normal size by 
imaging studies, and nodules related to WM should disappear. (Owen et al 2013 ) 
8.4.3 PARTIAL RESPONSE  
Partial response (PR) is defined as the regression of measurable disease and no new sites of dis ease.  
Regression is defined as greater than or equal to 50% decrease in the sum of the products of the 
diameters (SPD) of the index lesions, coupled with no unequivocal increase in size of other lymph nodes, liver or spleen.    No new sites of disease sho uld be observed.  If bone marrow was involved 
prior to therapy and a clinical CR was achieved but no bone marrow assessment is completed after treatment , then these patient s are considered partial  responders (Cheson et al., 2014 Lugano 
Classification ). 
For Waldenstrom’ s macroglobulinemia patients , partial response is defined as reduction of 
Monoclonal IgM protein between 50 -90 % from baseline with regression of measurable disease. 
Regression is defined as greater than or equal to 50% decrease in the sum of the products of the 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 38 of 68 diameters (SPD) of the index lesions, coupled with no unequivocal increase in size of other lymph 
nodes, liver or spleen.    No new sites of disease should be observed. (Owen et al 2013) 
8.4.4 MINOR RESPONSE  
A response criteria exclusive for Waldenstrom’ s macroglobulinemia patients , Minor Response (MR) 
is defined as presence of detectable Monoclonal IgM protein with reduction of monoclonal IgM 
protein greater than 25 % but less than 50 % from baseline. No new sites of disease should be observe d. (Owen et al 2013) 
8.4.5 STABLE DISEASE  
Stable disease is defined as the failure to attain CR/PR but does not fulfill the criteria for progressive 
disease.  For those with disease evaluated by CT only, there must be no unequivocal change in the 
size of the previous lesions on the post -treatm ent CT scan (Cheson et al., 2014 Lugano Classification ) 
For Waldenstrom ’s macroglobulinemia patients , stable disease is defined as  presence of detectable  
Monoclonal IgM protein with less than 25% reduction and less than 25% increase in serum IgM level 
from baseline . No unequivocal increase in size of other lymph nodes, liver or spleen. No new sites of 
disease should be observed. (Owen et al 2013) 
8.4.6 RELAPSED DISEASE OR PROGRESSION OF DISEA SE  
Any of the following conditions will  constitute relapsed or progressive disease:  
Appearance of any new lesion more than 1.5 cm in any axis, even if other lesions are decreasing in 
size will be considered relapsed or progressive disease.  Increase in FDG uptake in a previously 
unaffected site  should be confirmed with other modalities, a therapeutic decision should not be made 
solely on the basis of PET without histologic confirmation (Cheson et al., 20 14 Lugano Classification ). 
There is at least a 50% increase from nadir in one of the followin g:  
• The SPD of index lesions,  
• The greatest transverse diameter (GTD) of any individual previously involved node, or  
• The GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. (Cheson et al. , 2014 Lugano Classification ). 
For Waldenstrom ’s macroglobulinemia patients , progressive disease is defined as more than 25% 
increase in serum IgM level from lowest nadir and/or progression in clinical features attributable the 
disease. (Owen et al 2013 ) 
8.5 DEFINITIONS OF DISEA SE PARAMETERS  
Measurable disease :  Measurable lesions are defined as those that can be accurately measured in at 
least two dimensions with conventional techniques (CT, PET/CT, MRI, x -ray) and meet one of the 
following criteria: nodal lesion with a long axis > 1.5 cm re gardless of short axis, nodal lesion with 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 39 of 68 long and short axes > 1.0 cm, or extra- nodal lesions with long and short axes > 1.0 cm with spiral CT 
scan.  All tumor measurements should be recorded in centimeters .   
Non -measurable disease (evaluable disease) :  All other lesions (or sites of disease) including 
small lesions, (< 1.0 cm using spiral CT scan) are considered non- measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis, and cystic lesions are all 
non- measurable.   
Index lesions :  All measurable lesions up to a maximum of 6 nodal and extra- nodal lesions total, 
representative of all involved organs, should be i dentified as index lesions  and recorded and 
measured at baseline. For patients with splenic marginal zone lymphoma without lymphadenopathy, 
the spleen size should be used as an index lesion. Index lesions should be selected on the basis of 
their size (clearly measurable in two perpendicular dimensions)  and their suitabil ity for accurate 
repeated measurements (either by imaging techniques or clinically).  A baseline sum of product of 
the diameters (SPD) for all index lesions will be calculated and reported as the baseline SPD.  The 
baseline SPD will be used as reference to  further characterize any objective tumor regression in the 
measurable dimension of the disease.  
 
Non -index lesions :  All other lesions (or sites of disease) including any measurable lesions over and 
above the 6 index lesions should be identified as non -index lesions and should also be recorded at 
baseline.  Measurements of these lesions are not required, but the presence, absence, or in rare cases 
unequivocal progression of each should be noted throughout follow -up.  
8.6  EVALUATION OF BEST OVERALL RESPONSE  
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria as per the NHL established criteria used 
in this study (See Appendix A).  
8.6.1 DURATION OF RESPONSE  
Duration of response is defined as the time from documentation of a  response to treatment to the 
first documentation of tumor progression or death due to any cause , whichever comes first.  Duration 
of the response will be summarized using n (sample size), mean, standard deviation, median, 
minimum, and maximum for the resp onders.  
Duration of stable disease : 
Stable disease is measured from the start of the treatment  (Cycle 1/Day1)  until the criteria for 
progression are met.  
Progression -Free Survival : 
Progression free survival (PFS) is defined as the time from Cycle 1/Day1 to the first documentation 
of tumor progression or death due to any cause , whichever comes first.  This variable will be analyzed 
via Kaplan -Meier methodology.  The median PFS will be estimated.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 40 of 68 9 STATISTICAL CONSIDER ATIONS  
The sections of the Statistical C onsiderations describe the statistical methods to be used to analyze 
the efficacy and safety. These methods may be revised and updated due to reasons such as regulatory 
requirements or need for further clarifications. The final analysis plan will be documented in a formal statistical analysis plan (SAP) that must be finalized before database lock. The SAP will include details on how variables will be derived, how missing data will be handled, and how censoring procedures 
will be applied to time to event related variables as well as the details on statistical methods to be 
used for safety and efficacy analyses. The final clinical study report will discuss deviations from the 
SAP, if any.  
9.1 SAMPLE SIZE AND POWER 
 
 
 
9.2 GENERAL ANALYSIS CONV ENTION  
Unless otherwise stated, all analyses will be performed using SAS Version 9.2 or higher  and all 
hypothesis tests will be conducted at a two -sided significance level of 0.05.  
Summary tabulations will display the number of observations, mean, standard deviation, median, minimum, maximum, and appropriate percentiles for continuous variables, and the number and 
percentage by category for categorical data. Summaries will present data by treatment arm and 
overall, if appropriate.  The d ata listings will include all available efficacy and safety data.  
In general, safety and efficacy data will be presented by histology type and overall.  
9.3 ANALYSIS POPULATIONS  
The safety population will include all enrolled patients who have received at least one dose of study 
treatment.  The safety analyses will be based on this safety population.  
The modified Intent -to-Treat ( mITT) population will consist of all safety patient who have provided 
at least some post baseline efficacy assessment s.  The efficacy analyses will be based on this mITT 
population.  
9.4 PATIENT  DISPOSITION  
Patient disposition summaries will be presented by histology type and overall and will include t he 
number of patients enrolled and the number and percentage of enrolled patients in the m ITT and 
safety populations.  The summaries will also include the reasons for permanent discontinuation of 
study treatment and study.   

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 41 of 68 9.5 PATIENT  DEMOGRAPHICS AND BA SELINE CHARACTERISTI CS 
Baseline demographic and clinical characteristics wil l be summarized as percentages for categorical 
variables and as mean, standard deviation, median, minimum and maximum for continuous 
measures.  The analyses of baseline characteristics will be performed for the m ITT Population.   
9.6 MEDICAL HISTORY  
Medical history will be captured at the Screening visit.  Medical history will be coded using MedDRA and will be summarized by MedDRA system organ class and preferred term for the Safety population.  
9.7 EXTENT OF EXPOSURE  
The dose (mg) of study drugs administered, the total number of doses of study drugs, and the 
duration of treatment (number of study cycles) will be summarized with descriptive statistics.  The number and percentage of patients whose dose is modified at any time will be summarized by each type of modific ation by cycle and overall.  The proportion of patients completing each cycle of 
treatment will be summarized.  
9.8 EFFICACY ANALYSES   
Each patient will be assigned to  one of the following categories:  1) complete response, 2) partial 
response, 3) very good partial response , 4) minor response, 5) stable disease, 6) progres sive disease, 
7) early  death from malignant disease, 8) early death from toxicity, 9) early death because of other 
cause, or 10) unknown (not assessable, insufficient data).  
Many of the efficacy measures will be based on disease assessments.  The best clinical response as well as disease progression will be determined by an independent central radiology group ( ICRG) 
which will be blinded to treatment arm assignment.  Definitive disease progression will be based on standard criteria ( Cheson , B 20 14 Lugano Classification ; Appendix A – Criteria for Response 
Assessment  and Owen et al 2013  Appendix B).  
9.9 MISSING VALUE HANDLI NG PROCEDURES   
In general, other than for partial dates, missing data will not be imputed and will be treated as 
missing.  The algorithms for imputation of partial dates vary depending upon the parameter and are 
presented  in the Statistical Analysis Plan .   
9.10  STATISTICAL ANALYSES    
9.10.1  PRIMARY E FFICACY V ARIABLE  
The primary efficacy outcome is Overall Response Rate (ORR) .  The ORR is defined as percent of 
patients who achieve CR or PR  for MZL histology type patients  and is define d as percent of patients 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 42 of 68 who achieve CR , VGPR, PR or MR for WM histology type patients .  The estimated response rates as 
well as the two -sided 95% confidence interval of the response rate will be presented.   
9.10.2  EFFICACY V ARIABLE  
The secondary efficacy variable will include: 
• Complete Response ( CR) rate ; 
• Progression free survival (PFS);  
• Duration of response (DOR);  
• Time to Treatment Failure (TTF).  
These variables will be analyzed as appropriate.  
9.11  MULTIPLE COMPARISON PROCEDURES   
The study is a single treatment arm study.  No formal claims will be made.   
9.12  SAFETY ANALYSES  
Safety evaluations will be based on the incidence, intensity, and type of adverse events, as well as on 
clinically significant changes in the patient’s physical ex amination, vital signs, and clinical laboratory 
results.  Safety analyses will be performe d using the safety population.   Exposure to study treatment 
and reasons for discontinuation of study treatment will also be tabulated.  
9.13  ADVERSE E VENT CHARACTERISTICS  
CTCAE term (AE description) and grade:   The descriptions and grading scales found in the revised 
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.  All appropriate treatment areas should have access to a copy of the CTCAE version 4.0.  A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .     
‘Expectedness’:  AEs can be ‘Unexpected’ or ‘Expected’ for expedited  reporting purposes only. 
Expected AEs are defined as those described in the TGR -1202(umbralisib)  Investigator Brochure .  
Please refer to prescribing information for a listing of expected AEs.  
9.14  DEFINITIONS OF ADVER SE EVENTS  
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product. An AE does not necessarily have to have a causal 
relationship with this treatment.  An adverse event (AE) can therefore be any unfavorable and  
unintended sign (including an abnormal laboratory finding, for example), symptom, or disease 
temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes any occurrence that is new in onset or aggravated in severity or 
frequency from the baseline condition.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 43 of 68 In clinical studies, an AE can include an undesirable medical condition occurring at any time, 
including run -in or washout periods, even if no study treatment has been administered .  The NCI 
Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is to be used for the grading of severity of symptoms and abnormal findings.  For adverse events not covered by the NCI -CTCAE 
Version 4.0 grading system, the following definitions will be used:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2:  Moderate; minimal, local or non -invasive intervention indicated.  
• Grade 3: Severe or medically significant but not immediat ely life -threatening; hospitalization 
or prolongation of hospitalization indicated.  
• Grade 4: Life -threatening consequences; urgent intervention indicated.  
• Grade 5: Death related to AE. 
9.15  ADVERSE EVENTS (AE’S ) AND TREATMENT EMERGENT ADVERSE EVENTS 
(TEAE’S)  
All AEs and SAEs occurring on study will be listed by patient.  The frequency and percentages of 
patients with treatment- emergent adverse events (TEAEs) will be tabulated by system organ class 
(SOC) and preferred term (PT), where treatment -emergent is defined as any AE that:  
• Occurs after first dosing of study medication and through the end of the study or up through 30 days after the last dose of study treatment, or  
• Is considered treatment- related regardless of the start date of the event, or  
• Is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment -related.  
 
TEAEs that are considered at least possibly related to study treatment will be tabulated as well as 
deaths, SAEs, an d events resulting in treatment discontinuation.  
AEs that occur after informed consent but before first dosing of study medication will not be summarized but will be listed.   
At each level of summarization, a patient will be counted only once for each AE,  SOC, or PT 
experienced within that level.  In the summation for AE severity, within each level of AE, SOC, or PT 
experienced, the one with the highest severity will be included.  In the summation for AE’s relationship to the study drug, within each level of AE, SOC, or PT experienced, the one with the 
closest relationship to the study drug will be included.  
9.16  ADVERSE E VENTS/SERIOUS ADVERSE  EVENT CAUSALITY ASS ESSMENT  
The Investigator must also assess the relationship of any adverse event to the use of study d rugs 
(whether none, one, or both), based on available information, using the following guidelines:  
• Not Related : Clear -cut temporal and/or mechanistic relation to a cause other than the study 
drug(s).  
• Doubtful: There is no reasonable possibility that the ev ent is related to the study drug(s) but 
a definite cause cannot be ascertained.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 44 of 68 • Possible : There is still a reasonable possibility that the cause of the event was the study 
drug(s) but there exists a more likely cause of the event such as complications of p rogressive 
disease.  
• Probable : The most likely cause of the event is the study drug(s) but other causes cannot be 
completely excluded.  
• Definite: Clear cut temporal and/or mechanistic relation to the study drug(s).  All other 
causes have been eliminated.  Ev ents classified as definite will often be confirmed by 
documenting resolution on discontinuation of the study drug and recurrence upon 
resumption.  
9.16.1  RECORDING OF ADVERSE  EVENTS  
All adverse events of any patient during the course of the study will be reported  on the case report 
form, and the investigator will give his or her opinion as to the relationship of the adverse event to 
study drug treatment (i.e., whether the event is related or unrelated to study drug administration –
TGR- 1202 ).  If the adverse event is serious, it should be reported as soon as possible and no greater 
than 24 hours to the sponsor or designee.  Other untoward events occurring in the framework of a clinical study are also to be recorded as AEs (i.e., AEs that occur prior to assignment of study 
treatment that are related to a protocol- mandated intervention, including invasive procedures such 
as biopsies, medication washout, or no treatment run- in). 
All AEs regardless of seriousness or relationship to study drug treatment spanning from Cycle 1/Day 
1 until 30 calendar days after discontinuation or completion of protocol -specific treatment as defined 
by the protocol for that patient, are to be recorded on the eCRF . 
9.16.2  ABNORMAL LABORATORY VALUES AND VITAL SIG NS 
The reporting of abnormalities of vi tal signs as adverse events should be avoided.  Abnormalities of 
vital signs should not be reported unless any criterion for an SAE is fulfilled, the vital signs 
abnormalities cause the patient to discontinue study treatment, or the investigator insists th at the 
abnormality should be reported as an AE.  Abnormal laboratory results should be noted in the eCRF 
as an adverse event if they are associated with an overdose, require or prolong inpatient hospitalization, or are otherwise considered clinically significant by the investigator. If an abnormal laboratory value or vital sign is associated with clinical signs and/or symptoms, the sign or symptom should be reported as an AE, and the associated laboratory value or vital sign should be considered additional information that must be collected in the relevant eCRF.  If the laboratory abnormality is 
a sign of a disease or syndrome, only the diagnosis needs to be recorded on the SAE Report Form or 
AE eCRF.  
Clinical Laboratory Results will be summarized.  Summary statistics for actual values and for changes 
from baseline will be tabulated for laboratory results by scheduled visit.  Patients with laboratory 
values outside of the normal reference range at any post -baseline assessment will be summarized, 
and graded pe r NCI CTCAE Version 4.0 when applicable.  Patient incidence of abnormal laboratory 
results will be summarized by treatment group and maximum grade for each abnormal laboratory 
finding.  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 45 of 68 9.16.3  HANDLING OF ADVERSE EVENTS  
All adverse events resulting in discontinua tion from the study should be followed until resolution or 
stabilization.  Patients should be followed for AEs for 30 calendar days after discontinuation or 
completion of protocol -specific.  All new AEs occurring during this period must be reported and 
followed until resolution unless, in the opinion of the investigator, these values are not likely to 
improve because of the underlying disease.  In this case, the investigators must record his or her reasoning for this decision in the patient’s medical record  and as a comment on the eCRF .  After 30 
days, only AEs, SAEs, or deaths assessed by the investigator as treatment related are to be reported. 
9.17  SERIOUS ADVERSE EVEN TS 
9.17.1  DEFINITIONS OF SERIO US ADVERSE EVENTS  
The definitions of serious adverse events (SAEs) are  given below.  The investigator is responsible for 
ensuring that all staff involved in the study are familiar with the content of this section.  
An SAE or reaction is defined as any untoward medical occurrence that:  
• results in death, is immediately life -threatening,  
• requires at least a 24 -hour in -patient hospitalization or prolongation of existing 
hospitalization,  
• results in persistent or significant disability/incapacity, and/or  
• causes a congenital anomaly/birth defect.  
Medical and scientific judgment sho uld be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately life -
threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the previous definition.  These should also usually be considered serious.  Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscras ias or convulsions that do not result in 
hospitalization; or development of drug dependency or drug abuse.  
Progression of malignancy (including fatal outcomes), if documented by use of appropriate method 
(for example, as per IWG Cheson et al. 20 14, should not be reported as a serious adverse event.   
A suspected unexpected serious adverse reaction (SUSAR) is defined as an SAE that is suspected to 
be at least possibly related to study medication(s) and is an unexpected event. SUSAR reporting is 
encompassed within SAE reporting guidelines as defined in this section.  
Treatment within or admission to the following facilities is not considered to meet the criteria of “in -
patient hospitalization” (although if any other SAE criteria are met, the event must still be treated as 
an SAE and immediately reported):  
• Emergency Department or Emergency Room  
• Outpatient or same -day surgery units  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 46 of 68 • Observation or short -stay unit  
• Rehabilitation facility  
• Hospice or skilled nursing facility  
• Nursing homes, Custodial care or Respite ca re facility  
Hospitalization during the study for a pre -planned surgical or medical procedure (one which was 
planned prior to entry in the study), does not require reporting as a serious adverse event to the 
Sponsor.  
9.17.2  SERIOUS ADVERSE EVEN T REPORTING BY INVES TIGATORS  
It is important to distinguish between “serious” and “severe” adverse events, as the terms are not 
synonymous.  Severity is a measure of intensity; however, an AE of severe intensity need not necessarily be considered serious.  For  example, nausea which persists for several hours may be 
considered severe nausea, but may not be considered an SAE.  On the other hand, a stroke which 
results in only a limited degree of disability may be considered only a mild stroke, but would be 
conside red an SAE.  Severity and seriousness should be independently assessed when recording AEs 
and SAEs on the eCRF . 
Adverse events classified by the treating investigator as serious
 require expeditious handling and 
reporting to the Sponsor in order to comply w ith regulatory requirements.  Serious adverse events 
may occur at any time from the signing of the informed consent form through the 30 -day follow -up 
period after the last study treatment.  Sponsor or designee should be notified of all SAEs, regardless of causality, within 24 hours of the first knowledge of the event by the treating physician or research 
personnel.   
To report an SAE, see the appropriate form.  
All SAEs (regardless of causality assessment) occurring on study or within 30 days of last study 
treatment should be immediately reported to the sponsor as SAEs within the CRF and followed until 
resolution (with autopsy report if applicable).  
NHL progression or death due to NHL progression should be reported by the investigator as a serious 
adverse ev ent only if it is assessed that the study drugs caused or contributed to the NHL progression 
(i.e. by a means other than lack of effect).  Unrelated events of NHL progression should be captured 
on the appropriate eCRF.  
The investigator must review and sign  off on the SAE data on the SAE report.  The SAE should be 
reported to the Sponsor (or Sponsor designee).   
When an SAE is reported to the sponsor or designee, the same information should be entered on the 
eCRF within 24 hours (1 business day).  Transmission of the SAE report should be confirmed by the 
site personnel submitting the report.  
Follow- up information for SAEs and information on non -serious AEs that become serious should also 
be reported to the sponsor or designee as soon as it is available; these  reports should be submitted 
using the appropriate SAE form.  The detailed SAE reporting process will be provided to the sites in the Safety Monitoring Plan.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 47 of 68 Investigators must report SAEs and follow -up information to their responsible Institutional Review  
Board (IRBs)/Independent Ethics Committee according to the policies of the responsible IRB 
(Research Ethics Committee).  
9.18   SPONSOR SAE REPORTI NG REQUIREMENTS  
Sponsor is responsible for reporting relevant SAEs to the competent authority, other applicable 
regulatory authorities, and participating investigators, in accordance with ICH guidelines, FDA 
regulations, and/or local regulatory requirements.  
Sponsor is responsible for reporting unexpected fatal or life -threatening events associated with the 
use of the study drugs to the regulatory agencies and competent authorities within 7 calendar days 
after being notified of the event.  The Sponsor will report all related but unexpected SAEs including 
non- death/non -life-threatening related but unexpected SAEs (SUSAR)  associated with the use of the 
study medications to the regulatory agencies and competent authorities by a written safety report 
within 15 calendar days of notification.  Following the submission to the regulatory agencies and competent authorities, Inves tigators and trial sites will be notified of the SUSAR.  Investigators must 
report SUSARs and follow -up information to their responsible Institutional Review Board 
(IRBs)/Independent Ethics Committee according to the policies of the responsible IRB (Research 
Ethics Committee).  
9.19  RECORDING OF ADVERSE  EVENTS AND SERIOUS ADVERSE EVENTS  
Investigators should use correct medical terminology/concepts when recording AEs or SAEs on the SAE Report Forms and AE eCRF.  Avoid colloquialisms and abbreviations.  
All AEs, inc luding those that meet SAE reporting criteria, should be recorded on the AE eCRF; AEs 
that meet the definition of an SAE should additionally be reported.  
9.20  DIAGNOSIS VS. SIGNS AND SYMPTOMS  
All AEs should be recorded individually in the patient’s own words (verbatim) unless, in the opinion 
of the Principal Investigator or designated physician, the AEs constitute components of a recognized condition, disease, or syndrome.  In the latter case, the condition, disease, or syndrome should be named rather than each individual sign or symptom.  If a constellation of signs and/or symptoms 
cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded as an AE or SAE as appropriate on the relevant f orm(s) (SAE 
Report Form and/or AE eCRF).  If a diagnosis is subsequently established, it should be reported as 
follow -up information is available.  If a diagnosis is determined subsequent to the reporting of the 
constellation of symptoms, the signs/symptoms should be updated to reflect the diagnosis.  
9.20.1  PERSISTENT OR RECURRENT ADVERSE EVENTS  
A persistent AE is one that extends continuously, without resolution, between patient evaluation time 
points.  Such events should only be recorded once on the SAE Report F orm and/or the AE  eCRF.    If 
a persistent AE becomes more severe (changes from a Grade 1 or 2 AE to a Grade 3 or 4 AE) or lessens 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 48 of 68 in severity (changes from a Grade 3 or 4 AE to a Grade 1 or 2 AE), it should be recorded on a separate 
SAE Report Form and/or AE eCRF.   
A recurrent AE is one that occurs and resolves between patient evaluation time points, and 
subsequently recurs.  All recurrent AEs should be recorded on an SAE Report Form and/or AE  eCRF 
for each recurrence.  
9.20.2  ABNORMAL LABORATORY VALUES  
Abnormal laboratory results should be noted in the eCRF as an adverse event if they are associated 
with an overdose, require or prolong inpatient hospitalization, or are otherwise considered clinically significant by the investigator. If an abnormal laboratory valu e or vital sign is associated with clinical 
signs and/or symptoms, the sign or symptom should be reported as an AE, and the associated laboratory value or vital sign should be considered additional information that must be collected in the relevant eCRF.  If the laboratory abnormality is a sign of a disease or syndrome, only the diagnosis 
needs to be recorded on the SAE Report Form or AE eCRF.  
9.20.3  DEATHS  
Deaths that occur during the protocol -specified AE reporting period that are attributed by the 
investigator solely to progression of the patient’s NHL for up to 30 days post the last dose of study 
drug will be recorded on the appropriate study eCRF and rep orted on the Adverse Event page of the 
eCRF, i.e. are exempted from expedited reporting. All other on -study deaths, regardless of attribution, 
will be recorded on an SAE Report Form and expeditiously reported to the Sponsor.  
When recording a serious advers e event with an outcome of death, the event or condition that caused 
or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event page of the eCRF.  If the cause of death is unknown and cannot be ascertained at the time of reporting, record “Death NOS” on the eCRF Adverse Event page.  
9.20.4  HOSPITALIZATION, PROLONGED HOSPITALIZATI ON, OR SURGERY  
Any AE that results in hospital admission of >24 hours or prolongs hospitalization should be documented and reported as an SAE unless specifically instructed otherwise in this protocol.  There 
are some hospitalization scenarios that do not require reporting as an SAE when there is no 
occurrence of an AE.  See section 9.17.1 .   
9.20.5  PRE -EXISTING MEDICAL  CONDITIONS  
A pre -existing relevant medical condition is one that is present at the start of the study.  Such 
conditions should be recorded on the study’s appropriate medical history  eCRF.  A pre -existing 
medical condition should be recorded as an AE or SAE only if the frequency, severity, or character of 
the condition worsens during the study.  When recording such events on the appropriate SAE Report Form and/or AE  eCRF, it is import ant to convey the concept that the pre- existing condition has 
changed by including applicable descriptors.  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 49 of 68 9.20.6  PROTOCOL -DEFINED EVENTS OF SPECIAL INTER EST  
The following are events of special interest, and will need to be reported expeditiously: 
Pregnancy, Abortion, Birth Defects/Congenital Anomalies  
During the course of the study, all female patients of childbearing potential (the definitions of 
“women of childbearing potential” are listed in Error! Reference source not  found. ) must contact 
the treating investigator immediately if they suspect that they may be pregnant (a missed or late menstrual period should be reported to the treating investigator).   
If an investigator suspects that a patient may be pregnant prior to administration of study drug(s), 
the study drug(s) must be withheld until the result of the pregnancy test is confirmed.  If a pregnancy is confirmed, the patient must not receive any study drug(s), and must be discontinued from the study.   
If an investigator suspects that a patient may be pregnant after the patient has been receiving study drug(s), the study drug(s) must immediately be withheld until the result of the pregnancy test is confirmed.  If a pregnancy is confirmed, the study drug(s) must be immediately and permanently 
stopped, the patient must be discontinued from the study, and the investigator must notify the Study Chair or Medical Monitor as soon as possible.   
If a patient becomes pregnant while enrolled in the study, an SAE form should be completed and 
submitted to the Sponsor.  Abortions (spontaneous, accidental, or therapeutic) must also be reported 
to the Sponsor.  
Congenital anomalies/birth defects always
 meet SAE criteria, and should therefore be expeditiously 
reported as an SAE, using the previously described process for SAE reporting. 
Study Drug Overdose  
Symptomatic and non -symptomatic overdose must be reported in the eCRF.  Any accidental or 
intentional overdose with the study treatment that is symptomatic, even if not fulfilling a seriousness 
criterion, is to be reported to the Sponsor immediately (within 24 hours) using the corresponding 
SAE form, and following the same process described for SAEs.  If a study drug ov erdose occurs, 
patients should stop study drug dosing and be clinically monitored as appropriate, managing 
symptoms/side effects that may occur.  
Secondary Malignancy  
Any secondary malignancy event must be reported via the SAE form (in addition to the routi ne AE 
reporting mechanisms).  Any malignancy possibly related to cancer treatment should also be reported via the routine reporting mechanisms outlined in the protocol.  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 50 of 68 10 CLINICAL DATA COLLEC TION AND MONITORING  
10.1  SITE MONITORING  
A Sponsor representative or de signee will have made a site visit to each institution within 12 months 
prior to initiating the protocol to inspect the drug storage area, and fully inform the Investigator of 
his/her responsibilities for studies and the procedures for assuring adequate an d correct 
documentation.   
A study initiation site visit, a teleconference and/or a planned investigator meeting will be performed to review investigator responsibilities and protocol requirements.  During the initiation, the electronic case report forms ( eCRFs) and other pertinent study materials will be reviewed with the 
investigator’s research staff.  During the course of the study, the Sponsor will make visits to the sites as necessary in order to review protocol compliance, examine eCRFs, and individual patient  medical 
records, and ensure that the study is being conducted according to the protocol and pertinent regulatory requirements.  Selected eCRF entries will be verified with source documentation.  The review of medical records will be done in a man ner to assure that patient confidentiality is 
maintained.  
Site monitoring shall be conducted to ensure the human patient  protection, study procedures, 
laboratory, study intervention administration, and data collection processes are of high quality and 
meet  the Sponsor, GCP/ICH and, when appropriate, regulatory guidelines.  
10.2  AMENDMENTS TO THE PR OTOCOL  
Amendments to the protocol shall be planned, documented, and signature authorized prior to implementation.   
If an amendment to the protocol is required, the amendment will be originated and documented by 
the Sponsor.  All amendments require review and approval of the Sponsor and the Principal Investigator supporting the study.  The written amendment must be reviewed and approved by the 
Sponsor, and submitted to t he IRB at the investigator’s facility for the board’s approval.  
Amendments specifically involving change to study design, risk to patient, increase to dosing or 
exposure, patient  number increase, addition or removal of new tests or procedures, shall be reviewed 
and approved by the IRB at the Investigator’s facility. 
The amendment will be submitted formally to the FDA or other regulatory authorities by the Sponsor 
as applicable, an d specifically when an increase to dosing or patient exposure and/or patient  number 
has been proposed; or, when the addition or removal of an Investigator is necessitated.  
Items requiring a protocol amendment with IRB and Ethics Committee and/or FDA and Co mpetent 
Authority approval may include the following:  
• Change to study design  
• Risk to patient  
• Increase to dose or patient exposure to drug  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 51 of 68 • Patient  number increase of more than 20%  
• Addition or removal of tests and/or procedures  
• Addition/removal of a new I nvestigator  
It should be further noted that, if an amendment to the protocol substantially alters the study design 
or the potential risks to the patients, their consent to continue participation in the study should be 
obtained.  
10.3  CURRICULA VITAE AND FINANCIAL DISCLOSURE S 
All Principal Investigators will be required to submit to the Sponsor or its designee an up -to-date 
signed curriculum vitae (CV), current within two years, a current copy of their medical license, and a 
completed FDA form 1572 and fin ancial disclosure statement.  In addition, all sub -investigators will 
be required to submit to the Sponsor or its designee an up -to-date signed CV, current within two 
years, a current copy of their medical license, and a completed financial disclosure stat ement. 
10.4  DATA OWNERSHIP AND P UBLICATION  
By conducting this study, the Investigator affirms to Sponsor that he or she will maintain, in strict confidence, information furnished by the Sponsor including data generated from this study and 
preliminary laboratory  results, except as exempted for regulatory purposes.  
All data generated during the conduct of this study is owned by the Sponsor and may not be used by the Investigator or affiliates without the expressed written consent of the Sponsor.  
All manuscripts, abstracts, or other presentation materials generated by site investigators must be reviewed and approved by the Sponsor prior to submission.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 52 of 68 11 ETHICAL, FINANCIAL, AND REGULATORY CONSI DERATIONS  
This study  will be conducted according to the standards of Good C linical Practice outlined in the ICH 
E6 Tripartite Guideline and CFR Title 21 part 312, applicable government regulations, institutional 
research policies and procedures and any other local applicable regulatory requirement(s).  
11.1  IRB APPROVAL  
The study prot ocol, ICF, IB, available safety information, patient documents (e.g.,  study diary), patient 
recruitment procedures (e.g., advertisements), information about payments (i.e., PI payments) and 
compensation available to the patients and documentation evidencin g the PI’s qualifications must be 
submitted to the IRB for ethical review and approval prior to the study start.   
The PI/Sponsor and/or designee will follow all necessary regulations to ensure initial and ongoing, IRB study review. The PI/Sponsor (as appropriate) must submit and, where necessary, obtain approval from the IRB for all subsequent protocol amendments and changes to the informed consent document.  Investigators will be advised by the sponsor or designee whether an amendment is 
considered substa ntial or non- substantial and whether it requires submission for approval or 
notification only to an IRB.  
If applicable, the PI will notify the IRB within 90 days  of the end of the study, or if the study 
terminates early, the PI must notify the IRB within 1 5 days  of the termination.  A reason for the early 
termination must be provided (as defined in Directive 2001/20/EC). The Sponsor will either prepare or review all submission documents prior to submission to the IRB.  
11.2  REGULATORY APPROVAL  
As required by local regulations, the Sponsor will ensure all legal aspects are covered, and approval 
of the appropriate regulatory bodies obtained, prior to study  initiation. If required, the Sponsor will 
also ensure that the implementation of substantial  amendment to the protocol and other relevant 
study  documents happen only after approval by the relevant regulatory authorities.  
Safety updates for TGR- 1202 (umbralisib)  will be prepared by the Sponsor or its representative as 
required, for submission to t he relevant regulatory authority.   Insurance and Indemnity 
Details of insurance and/or indemnity will be contained within the written agreement between the 
PI or site and the Sponsor. 
11.3  INFORMED CONSENT  
Informed consent is a process by which a patient  volun tarily confirms his or her willingness to 
participate in a particular study , after having been informed of all aspects of the study  that are 
relevant to the patient 's decision to participate.  Informed consent is documented by means of a 
written, signed an d dated informed consent form.  
The ICF will be submitted for approval to the IRB that is responsible for review and approval of the 
study .  Each consent form must include all of the relevant elements currently required by the 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 53 of 68 responsible regulatory authority, as well as local county authority or state regulations and national 
requirements.  
Before recruitment and enrollment into the study , each prospective candidate will be given a full 
explanation of the study .  Once the essential information has been provided to the prospective 
candidate, and the investigator is sure that the individual candidate understands the implications of 
participating in this study , the candidate will be asked to give consent to participate in the study  by 
signing an informed consent form.  A notation that written informed consent has been obtained will be made in the patient’s medical record.  A copy of the informed consent form, to include the patient’s 
signature, will be provided by the investigator to the patient.   
If an amendment to the protocol substantially alters the study  design or the potential risks to the 
patients, the patient’s consent to continue participation in the study  must be obtained.  
11.4  CONFIDENTIALITY  
Patient Confidentiality  
Confidentiality of patient’s perso nal data will be protected in accordance with the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA), and national data protection laws. HIPAA regulations require that, in order to participate in the study , a patient must sign an authorization 
from the study  that he or she has been informed of following:  
• What protected health information (PHI) will be collected from patients in this study ; 
• Who will have access to that information and why;  
• Who will use or disclose that information;  
• That hea lth information may be further disclosed by the recipients of the information, and 
that if the information is disclosed the information may no longer be protected by federal or 
state privacy laws;  
• The information collected about the research study  will be  kept separate from the patient’s 
medical records, but the patient will be able to obtain the research records after the 
conclusion of the study ; 
• Whether the authorization contains an expiration date; and  
• The rights of a research patient to revoke his or her authorization.  
In the event that a patient revokes authorization to collect or use his or her PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of patient authorization.  For patients tha t have revoked authorization to collect or use PHI, attempts should be 
made to obtain permission to collect at least vital status (i.e., that the patient is alive) at the end of 
their scheduled study  period.  
In compliance with ICH GCP guidelines and applic able parts of 21 CFR it is a requirement that the 
investigator and institution permit authorized representatives of the Sponsor, the regulatory 
authorities and the IRB direct access to review the patient’s original medical records at the site for 
verificat ion of study -related procedures and data.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 54 of 68 Measures to protect confidentiality include: only a unique study  number and initials will identify 
patients on the e CRF or other documents submitted to the Sponsor. This information, together with 
the patient’s da te of birth, will be used in the database for patient identification. Patient names or 
addresses will not be entered in the eCRF or database. No material bearing a patient’s name will be 
kept on file by the Sponsor. Patients will be informed of their rights within the ICF.  
11.5  INVESTIGATOR AND STAFF INFORMATION  
Personal data of the investigators and sub -investigators may be included in the Sponsor  database, 
and shall be treated in compliance with all applicable laws and regulations.  When archiving or 
processin g personal data pertaining to the investigator or sub -investigator, the Sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by any unauthorized party.  
11.6  FINANCIAL INFORMATIO N  
The finances for this study  will be patient  to a separate written agreement between the Sponsor and 
applicable parties.  Any Investigator financial disclosures as applicable to 21CFR Part 54 shall be 
appropriately provided.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 55 of 68 12 RECORD RETENTION AND DOCUMENTATION OF TH E STUDY  
12.1  DOCUMENTATION REQUIR ED TO INITIATE STUDY  
Before the study may begin, certain documentation required by FDA regulations must be provided 
by the Investigator.  The required documentation should be submitted to the Sponsor.  
Documents at a minimum required to begin the study include, bu t are not limited to, the following:  
• A signature -authorized protocol and contract;  
• A copy of the official IRB approval of the study and the IRB members list;  
• Current Curricula Vita for the principal investigator and any associate investigator(s) who 
will b e involved in the study;  
• Indication of appropriate accreditation for any laboratories to be used in the study and a copy 
of the normal ranges for tests to be performed by that laboratory;  
• Original Form FDA 1572 (Statement of Investigator), appropriately co mpleted and signed;  
• A copy of the IRB -approved consent form containing permission for audit by representatives 
of the Sponsor, the IRB, and the FDA;  
• Financial disclosure forms for all investigators listed on Form FDA 1572;  
• GCP Certificate for study traini ng; 
• Site qualification reports, where applicable;  
• Verification of Principal Investigator acceptability from local and/or national debarment list(s).  
The Sponsor/Sponsor designee will ensure that all documentation that is required to be in place before the study may start, in accordance with ICH E6 and Sponsor SOPs, will be available before any 
study sites are initiated.  
12.2  STUDY DOCUMENTATION AND STORAGE  
The PI must maintain a list of appropriately qualified persons to whom he/she has delegated study 
duties an d should ensure that all persons assisting in the conduct of the study are informed of their 
obligations. All persons authorized to make entries and/or corrections on the e CRFs are to be 
included on this document. All entries in the patient’s eCRF are to b e supported by source 
documentation where appropriate.  
Source documents are the original documents, data, records and certified copies of original records of clinical findings, observations and activities from which the patient’s eCRF data are obtained. 
These can include, but are not limited to, hospital records, clinical and office charts, laboratory, 
medico -technical department and pharmacy records, diaries, microfiches, EKG traces, copies or 
transcriptions certified after verification as being accurate a nd complete, photographic negatives, 
microfilm or magnetic media, X- rays, and correspondence.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 56 of 68 The PI and study staff are responsible for maintaining a comprehensive and centralized filing system 
(Site Study File/SSF or ISF) of all study -related (essential)  documentation, suitable for inspection at 
any time by representatives from the Sponsor and/or applicable regulatory authorities.  The ISF/SSF must consist of those documents that individually or collectively permit evaluation of the conduct of 
the study a nd the quality of the data produced.  The ISF/SSF should contain as a minimum all relevant 
documents and correspondence as outlined in ICH GCP Section 13 and 21 CFR Part 312.57, including 
key documents such as the IB and any amendments, protocol and any am endments, signed ICFs, IRB 
approval documents, Financial Disclosure forms, patient identification lists, enrollment logs, delegation of authority log, staff qualification documents, laboratory normal ranges, records relating to the study drug including acc ountability records.  Drug accountability records should, at a 
minimum, contain information regarding receipt, shipment, and disposition.  Each form of drug accountability record, at a minimum, should contain PI name, date drug shipped/received, date, quan tity and batch/code, or lot number for identity of each shipment.  In addition, all original source 
documents supporting entries in the eCRF must be maintained and be readily available.  
The Sponsor shall maintain adequate investigational product records an d financial interest records 
as per 21CFR Part 54.6 and Part 312.57 for no less than 2 years after the last marketing application has been approved by FDA; or, in the event that the marketing application has not been approved by FDA, for no less than 2 years after the last shipment / delivery of the drug for investigational use is 
discontinued and FDA has been notified of the discontinuation.  
The IRB shall maintain adequate documentation / records of IRB activities as per 21CFR Part  56.115 
for at least 3 years after completion of the research. 
The Investigator shall maintain adequate records of drug disposition, case histories and any other 
study -related records as per 21 CFR Part 312.62 for no less than 2 years after the last marketing 
application has been approved by FDA; or, in the event that the marketing application has not been 
approved by FDA, for no less than 2 years after the last shipment / delivery of the drug for 
investigational use is discontinued and FDA has been notified of the discontinuation.  
To enable evaluations and/or audits from regulatory authorities or from the Sponsor or its 
representative, the investigator additionally agrees to keep records, including the identity of all participating patients (sufficient information to link records e .g., medical records), all original, signed 
informed consent forms, and copies of all e CRFs, SAE Reporting forms, source documents, detailed 
records of treatment disposition, and related essential regulatory documents.  The documents listed 
above must be retained by the investigator for as long as needed to comply with national and international regulations (generally 2 years after discontinuing clinical development or after the last marketing approval).  The Sponsor or its representative will notify the in vestigator(s)/institutions(s) 
when the study -related records are no longer required.   
If the investigator relocates, retires, or for any reason withdraws from the study, either  the Sponsor 
or its representative should be prospectively notified.  The study  records must be transferred to an 
acceptable designee, such as another investigator, another institution, or to sponsor.  The investigator must obtain the sponsor written permission before disposing of any records, even if 
retention requirements have been  met.  All study files will be maintained by the Sponsor or its 
representative throughout the study, and will be transferred to the Sponsor at the conclusion of the study.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 57 of 68 12.3  DATA COLLECTION  
The study eCRF is the primary data collection instrument for the study. An electronic case report 
form will be utilized for the collection of all data and all data will be entered using the English 
language and should be kept current to enable the monitor to review the patients’ status throughout 
the course of the study . 
In order to maintain confidentiality, only study number, patient number, initials and date of birth will 
identify the patient in the eCRF.  If the patient’s name appears on any other document (e.g.  laboratory 
report), it must be obliterated on the copy o f the document to be supplied to the investigator site and 
replaced instead with the patient number and patient’s initials.  The investigator will maintain a 
personal patient identification list (patient numbers with corresponding patient identifiers) to enable records to be identified and verified as authentic. Patient data/information will be kept 
confidential, and will be managed according to applicable local, state, and federal regulations.  
12.4  STUDY  MONITORING, AUDITIN G, AND INSPECTING  
The investigator will permit study -related monitoring, quality audits, and inspections by government 
regulatory authorities, the Sponsor or its representative(s) of all study -related documents (e.g., 
source documents, regulatory documents, data collection instruments, case report forms).  The investigator will ensure the capability for inspections of applicable study -related facilities.  The 
investigator will ensure that the study monitor or any other compliance or QA reviewer is given 
access to all study -related documents and study -related facilities.   
Participation as an investigator in this study implies the acceptance of potential inspection by government regulatory authorities and the sponsor or its representative(s).  
At the Sponsor’s discretion, Source Document Verifica tion (SDV) may be performed on all data items 
or a percentage thereof.  
12.5  QUALITY ASSURANCE AND QUALITY CONTROL  
In addition to the Clinical Monitoring component of this protocol, the Sponsor’s Quality Assurance 
(QA) department shall establish an Auditing Plan  document separate from the protocol to establish 
the criteria by which independent auditing shall be conducted during the conduct of the study to assess compliance with GCP and applicable regulatory requirements.  Data or documentation audited shall be as sessed for compliance to the protocol, accuracy in relation to source documents and 
compliance to applicable regulations.  
Each study site shall be required to have Standard Operating Procedures (SOP’s) to define and ensure quality assurance/control process es for study conduct, data generation & collection, recording of 
data/documentation and reporting according to the protocol, GCP and any applicable local, national 
or international regulations.  
Accurate and reliable data collection will be ensured by verif ication and cross check of the eCRFs 
against the investigator’s records by the study monitor (source document verification) and by the 
maintenance of a drug –dispensing log by the investigator.  Collected data will be entered into a 
computer database and subject to electronic and manual quality assurance procedures.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 58 of 68 12.6  DISCLOSURE AND PUBLI CATION POLICY  
All information provided regarding the study, as well as all information collected/documented 
during the course of the study, will be regarded as confidential.  The Sponsor reserves the right to 
release literature publications based on the results of the study.  
A clinical study report will be prepared upon completion of the study.  The Sponsor will disclose the study results, in the form of a clinical study report  synopsis, to the IEC and the applicable regulatory 
authorities within one year of the end of the study.  The format of this synopsis and that of the clinical study report and its addendum will comply with ICH E3 guidelines for structure and content of a 
clinical study report.  
The financial disclosure information will be provided to the Sponsor prior to study participation from all PIs and Sub -Investigators who are involved in the study and named on the FDA 1572 form.  
By conducting this study, the Investigator affirms to the Sponsor that he or she will maintain, in strict 
confidence, information furnished by the Sponsor including data generated from this study and 
preliminary laboratory results, except as exempted for regulatory purposes.  
All data generated during the conduct of this study is owned by the Sponsor and may not be used by 
the Investigator or affiliates without the expressed written consent of the Sponsor.  
All manuscripts, abstracts, or other presentation materials generated by site investigator s must be 
reviewed and approved by the Sponsor prior to submission.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 59 of 68 13 REFERENCES  
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., . . . Diehl, V. (2007). Revised 
response criteria for malignant lymphoma. Journal of Clinical Oncology, 25 (5), 579 -586. doi: 
10.1200/JCO.2006.09.2403  
Cheson, B.C., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E., Lister, T.A. (2014). 
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-
hodgkin lymphoma: The Lugano classification. Journal of Clinical Oncology,  32, (1 -10). doi: 
10.1200/JCO.2013.54.8900  
de Romeuf C, D. C., Le Garff -Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, 
Beliar d R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JC, Merle -Beral H. (2008). Chronic 
lymphocytic leukaemia cells are effeciently killed by an anti -CD20 monoclonal antibody selected for 
improved engagement of FcgammaRIIIA/CD16. British Journal of Haem atology, 6 (140), 635 -643.  
Esteves IT, D. C., Herveau S, Reslan L, Brune F, Van Overtvelt L, Salcedo M, Fournes B. (2011). LFB -R603 
(ublituximab), a third- generation monoclonal anti- CD20 antibody, displays additive antitumor activity 
with antileukemic chemotherpeutic agents in mouse xenograft models. American Society of 
Hematology , abstract 1660.  
Friedberg, J. W. (2011). Relapsed/Refractory diffuse large b -cell lymphoma. Hematology , 498 -505.  
Genentech. (2014). Rituxan® prescribing information.  
Lunning, M. A., Vose, J. M., Schreeder, M. T., Fowler, N., Nastoupil, L., Siddiqi, T., . . . O'Brien, S. (2014). 
Ublituximab, a novel glycoengineered anti -CD20 mAb, in combination with TGR -1202, a next generation 
once daily PI3Kdelta inhibitor, demonstrates activity in heavily pre -treated and high -risk chronic 
lymphocytic leukemia and B -cell lymphoma.  Paper presented at the American Society of Hematology, 
San Francisco, CA.  
NCCN. (201 5). NCCN guidelines: Non -Hodgkin's Lymphomas (Vol. Version 2.2015).  
O'Conn or, O. A., Schreeder, M. T., Deng, C., Amengual, J. E., Boccia, R., Khalil, M. Y., . . . Farber, C. M. (2014). 
Ublituximab (TG -1101), a novel anti -cd20 monoclonal antibody for rituximab relapsed/refractory B -cell 
malignancies.  Paper presented at the Europe an Hematology Association, Milan, Italy.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 60 of 68  (2011). PI3Kgamma enzyme assay. Shameerpet, India: Incozen Therapeutics.  
Rosenwa
ld, A., Wright, G., Chan, W. c., Connors, J. M., Campo, E., Fisher, R. I., . . . Staudt, L. M. (2002). The use of 
molecular profiling to predict survival after chemotherapy for diffuse large -b-cell lymphoma. New 
England Journal of Medicine, 346 (25), 1937 -1947.  
 (2011a). AKT phosphorylation in MOLT -4 cells. June Study Report IVT -5264 -APM -10. Shameerpet, 
India: Incozen Therapeuticis PVT Ltd.  
 (2011b). AKT phosphorylation in THP -1 cells. Study Report IVT -5264 -ATP -08. Shameerpet, India: 
Incozen Therapeuticis PVT Ltd.  
Therapeutics, T. (2014). Ublituximab (TG -1101) Investigator's Brochure (Vol. Vers ion 3.0).  
Owen, R. G. et al.  Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel 
Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. 
Seminars in Oncology  30, 110 –115 (2003).  
.Owen, R. G. , et al Response assessment in Waldenström macroglobulinaemia: update from the VIth 
International Workshop. Br J Haematol, 160: 171 –176. doi:10.1111/bjh.12102 (2013)  
 
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 61 of 68 14 APPENDIX A –CRITERIA FOR RESPONS E ASSESSMENT  
Revised Response Criteria for Non - Hodgkin ’s Lymphoma (Cheson et. al. 20 14 Lugano 
Classification ) 
Response and Site  PET -CT–Based Response  CT-Based Response  
Complete Response    
Lymph nodes and extra -
lymphatic sites  
 Score 1, 2, or 3 * with or without a 
residual mass on 5PS † 
It is recognized that in Waldeyer's 
ring or extra -nodal sites with high 
physiologic uptake or with 
activation within spleen or marrow (eg, with chemotherapy or myeloid colony -
stimulating factors), uptake 
may be greater than normal 
mediastinum and/or liver. In this 
circumstance, complete metabolic 
response may be inferred if uptake at sites of initial involvement is no 
greater than surrounding normal 
tissue even if the ti ssue has high 
physiologic uptake  Target nodes/nodal masses must 
regress to ≤ 1.5 cm in LDi  
No extra -lymphatic sites of disease  
Non - measured lesion  Not applicable  Absent  
Organ enlargement  Not applicable  Regress to normal  
New lesions  None  None  
Bone marrow  No evidence of FDG -avid disease in 
marrow  Normal by morphology; if 
indeterminate, IHC negative  
Partial Response    
Lymph nodes and extra -
lymphatic sites  Score 4 or 5 † with reduced uptake 
compared with baseline and 
residual mass(es) of any size  
At interim, these findings suggest 
responding disease  
At end of treatment, these findings 
indicate residual disease  ≥ 50% decrease in SPD of up to 6 
target measurable nodes and extra -
nodal sites  
When a lesion is t oo small to measure 
on CT, assign 5 mm × 5 mm as the 
default value  
When no longer visible, 0 × 0 mm  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 62 of 68 For a node > 5 mm × 5 mm, but 
smaller than normal, use actual 
measurement for calculation  
Non - measured lesion  Not applicable  Absent/normal, regressed, but  no 
increase  
Organ enlargement  Not applicable  Spleen must have regressed by > 
50% in length beyond normal  
New lesions  None  None  
Bone marrow  Residual uptake higher than uptake 
in normal marrow but reduced 
compared with baseline (diffuse 
uptake compatible with reactive 
changes from chemotherapy 
allowed). If there are persistent 
focal changes in the marrow in the 
context of a nodal response, 
consideration should be given to 
further evaluation with MRI or 
biopsy or an interval scan  Not applicable  
No respons e or stable 
disease    
Target nodes/nodal masses, 
extra -nodal lesions  Score 4 or 5 with no significant 
change in FDG uptake from baseline 
at interim or end of treatment  < 50% decrease from baseline in SPD 
of up to 6 dominant, measurable 
nodes and extra -nodal sites; no 
criteria for progressive disease are 
met  
Non -measured lesions  Not applicable  No increase consistent with 
progression  
Organ enlargement  Not applicable  No increase consistent with 
progression  
New lesions  None  None  
Bone marrow  No change from baseline  Not applicable  
Progressive disease    
Individual target 
nodes/nodal masses, Extra -
nodal lesions  Score 4 or 5 with an increase in 
intensity of uptake from baseline 
and/or  new FDG -avid foci 
consistent with lymphoma at PPD Progression:  
An individual node/lesion must be 
abnormal with:  
- LDi > 1.5 cm  
- Increase by ≥ 50% from PPD nadir.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 63 of 68 Abbreviations: 5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, 
immunohistochemistry; LDi, longest transve rse diameter of a lesion; MRI, magnetic resonance 
imaging; PET, positron emission tomography; PPD, cross product of the LDi and perpendicular 
diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product of the perpendicular 
diameters for multiple lesions.*A score of 3 in many patients indicates a good prognosis with 
standard treatment, especially if at the time of an interim scan. However, in trials involving PET 
where de -escalation is investigated, it may be preferable to consider a score of 3 as inadequate 
response (to avoid undertreatment). Measured dominant lesions: Up to six of the largest dominant 
nodes, nodal masses, and extra- nodal lesions selected to be clearly measurable in two diameters. 
Nodes should preferably be from disparate regions of the body and should include, where applicable, 
mediastinal and retroperitoneal areas. Non -nodal lesions include those in solid organs (eg, liver, 
spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. Non -
measur ed lesions: Any disease not selected as measured, dominant disease and truly assessable 
disease should be considered not measured. These sites include any nodes, nodal masses, and extra -
nodal sites not selected as dominant or measurable or that do not meet  the requirements for 
measurability but are still considered abnormal, as well as truly assessable disease, which is any site 
of suspected disease that would be difficult to follow quantitatively with measurement, including 
pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions 
that cannot be confirmed and followed by imaging. In Waldeyer's ring or in extra -nodal sites (eg, GI interim or end -of-treatment 
assessment  An increase in LDi or SDi from nadir  
- 0.5 cm for lesions ≤ 2 cm  
- 1.0 cm for lesions > 2 cm  
In the setting of splenomegaly, th e 
splenic length must increase by > 
50% of the extent of its prior 
increase beyond baseline (eg, a 15 -
cm spleen must increase to > 16 cm). If no prior splenomegaly, must increase by at least 2 cm from 
baseline.  
New or recurrent splenomegaly.  
Non -measured lesions  None  New or clear progression of 
preexisting non -measured lesions  
New lesions  New FDG -avid foci consistent with 
lymphoma rather than another etiology (eg, infection, inflammation). If uncertain regarding etiology of new lesions, 
biopsy or interval  scan may be 
considered  Regrowth of previously resolved 
lesions  
A new node > 1.5 cm in any axis  
A new extra -nodal site > 1.0 cm in 
any axis; if < 1.0 cm in any axis, its 
presence must be unequivocal and must be attributable to lymphoma  
Assessable disease o f any size 
unequivocally attributable to 
lymphoma  
Bone marrow  New or recurrent FDG -avid foci  New or recurrent involvement  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 64 of 68 tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum with co mplete 
metabolic response, but should be no higher than surrounding normal physiologic uptake (eg, with 
marrow activation as a result of chemotherapy or myeloid growth factors).†PET 5PS: 1, no uptake 
above background; 2, uptake ≤ mediastinum; 3, uptake > mediastinum but ≤ liver; 4, uptake 
moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake 
unlikely to be related to lymphoma  
Consensus -based uniform response criteria for WM developed by the IWWM, updated 
in the sixth  IWWM  
Complete response (CR)  Absence of serum monoclonal IgM protein by immunofixation.  
Normal serum IgM level.  
Complete resolution of extramedullary disease, i.e., 
lymphadenopathy and splenomegaly if present at baseline. 
Morphologically  normal bone marrow aspirate and trephine 
biopsy  
Very good partial response (VGPR)  Monoclonal IgM protein is detectable ≥90% reduction in serum 
IgM level from baseline  
Complete resolution of extramedullary disease, i.e., 
lymphadenopathy/splenomegaly if present at baseline. No new 
signs or symptoms of active disease  
Partial response (PR)  Monoclonal IgM protein is detectable.≥50% but<90% 
reduction in serum IgM level from baseline. Reduction in 
extramedullary disease, i.e., lymphadenopathy/splenomegaly if 
present at baseline. No new signs or symptoms of active disease  
Minor response (MR)  Monoclonal IgM protein is detectable  
≥25% but<50% reduction in serum IgM level from baseline  
No new signs or symptoms of active disease  
Stable disease  Monoclonal IgM protein is detectable  
<25% reduction and <25% increase in serum IgM level from 
baseline 
 
No progression in extramedullary disease, ie, 
lymphadenopathy/splenomegaly  
 
No new signs or symptoms of active disease  
Progressive disease  ≥25% increase in serum IgM level* †from lowest nadir (requires 
confirmation) and/or progression in clinical features 
attributable the disease  
 

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 65 of 68 15 APPENDIX B- CONTRACEPTIVE GUID ELINES AND PREGNANCY  
Women Not of Childbearing Potential are Defined as Follows:  
Women are considered post -menopausal and not of child bearing potential if they have had 12 
months o f natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum 
FSH levels > 40 mIU/mL [for US only: and estradiol <  20 pg/mL] or have had surg ical bilateral 
oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone 
level assessment is she considered not of child bea ring potential.  
Contraceptive Guidelines for Women of Child-Bearing Potential:  
Women of child -bearing potential, defined as all women physiologically capable of becoming 
pregnant, must use highly effective contraception during the study and for  30 days  after stopping 
treatment. The highly effective contraception is defined as either:  
1. True abstinence: When this is in line with the preferred and usual lifestyle of the patient . 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation m ethods) and 
withdrawal are not acceptable methods of contraception.  
2. Sterilization:  have had surgical bilateral oophorectomy (with or without hysterectomy) or 
tubal ligation at least six weeks ago.  In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level 
assessment.  
3. Male partner sterilization (with the appropriate post -vasectomy documentation of the 
absence of sperm in the ejaculate). For female patient s on the study, the vasectomised male 
partner should be the sole partner for that patient.  
4. Oral contraception, injected or implanted hormonal methods.  
5. Use of a combination of any two of the following (a+b):  
a. Placement of an intrauterine device (IUD) or intrauterine system (IUS).  
b. Barrier methods  of contraception: Condom or Occlusive cap (diaphragm or   
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.  
The following are unacceptable
 forms of contraception for women of childbearing potential:  
• Female condom  
• Natural family planning (rhythm method) or breastfeeding  
• Fertility awareness  
• Withdrawal  
• Cervical shield  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 66 of 68 Women of child -bearing potential must have a negative serum or urine pregnancy test ≤ 72 hours 
prior to initiating treatment.  
Fertile Males:  
Fertile males, defined as all males physiologically capable of conceiving offspring , must use condom s 
during the treatment  period  and for  30 days  after study drug discontinuation  and should not father 
a child in this period .  
Pregnancies  
To ensure patient safety, each pregnancy in a patient on study treatment must be reported to TG 
Therapeutics Inc. with in 24 hours of learning of its occurrence. The pregnancy should be followed up 
for 3 months after the termination of the pregnancy to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of an y birth defects, 
congenital abnormalities, or maternal and/or newborn complications.  
Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported by the investigator to TG Therapeutics Inc.  Pregnancy follow -up should be recorded on the same form and should 
include an assessment of the possible relationship to the study drug and reported by the investigator to TG Therapeutics Inc.  Any SAE experienced during pregnancy must be reported on the SAE Report 
Form.  
Pregnancy outcomes must be col lected for the female partners of any males who took study 
treatment in this study.  Consent to report information regarding these pregnancy outcomes should be obtained from the mother.  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 67 of 68 16 APPENDIX C – NYHA CLASSIFICATI ONS  
New York Heart Association (NYHA) Classifications  
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting 
limitations of physical activity.  Ordinary physical 
activity does not cause undue fatigue, palpitation, 
dyspnea, or anginal pain.  No objective evidence of 
cardiovascular disease.  
II Patients with cardiac disease resulting in slight 
limitation of physical activity.  They are comfortable at 
rest.  Ordinary physical activity results in fatigue, 
palpitation, dyspnea, or anginal pain.  Objec tive evidence of 
minimal cardiovascular 
disease.  
III Patients with cardiac disease resulting in marked 
limitation of physical activity.  They are comfortable at 
rest.  Less than ordinary activity causes fatigue, 
palpitation, dyspnea, or anginal pain.  Objective evidence of 
moderately severe 
cardiovascular disease.  
IV Patients with cardiac disease resulting in inability to 
carry on any physical activity without discomfort.  
Symptoms of heart failure or the anginal syndrome may 
be present even at rest.  If any physical activity is 
undertaken, discomfort is increased.  Objective evidence of 
severe cardiovascular 
disease.  
Source:  The Criteria Committee of New York Heart Association.  Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Grea t Vessels.  9th Ed. Boston, MA:  Little, Brown & Co; 
1994:253 -256.  
 
  

TGR- 1202 -202   
Dated: 5 September 2017 (Ver. 2.0)   Page 68 of 68 17 APPENDIX D – HEPATITIS B SEROLOGIC TEST RESULTS  
 
